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Chapter 1
General introduction
Partly based on:
Stallmann, H.P., Faber, C., Nieuw Amerongen, A.V., and Wuisman, P.I. (2006). 
Antimicrobial peptides: review of their application in musculoskeletal infections. 
Injury 37 Suppl 2, S34-S40.
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Osteomyelitis
 Osteomyelitis is a refractory condition (ﬁ gure 1), potentially leading to 
amputation or even death. Treatment often requires multiple surgical interventions and 
local or systemic antibiotic therapy (Cierny, III et al., 2003). It predominantly affects 
both extremes of age; acute hematogenous infection occurs mainly in children and 
chronic osteomyelitis in the elderly (Le Saux et al., 2002). Implant surfaces constitute a 
safe haven for pathogens, frustrating fracture treatment and arthroplasty. 
 The old adage -once osteomyelitis always osteomyelitis- has not lost its 
relevance. The multifactorial nature of these infections demands an approach that 
attends to all aspects related to patient, wound, implant and pathogen. This implies that 
no single solution will work in all cases. Despite controversy on the use of prophylactic 
local antibiotic treatment, using antibiotic-containing cement seems to be justiﬁ ed 
(Engesaeter et al., 2003). In the case of established infection, surgical debridement 
of all infected tissues would be combined with local and systemic antibiotic therapy. 
Additional measures to improve the patient’s immune status, reduce tissue trauma and 
optimize implant surfaces will further decrease the occurrence of osteomyelitis. 
 Local treatment of infection has favorable pharmacokinetics (ﬁ gure 2): it 
produces high concentrations at the infectious focus without systemic toxicity (Henry 
et al., 1995). In the 1970s Buchholz introduced the concept of antibiotic containing 
polymethyl-methacrylate (PMMA) cement for prevention of infection (Buchholz et al., 
1970).
 
Figure 1: Chronic osteomyelitis with a central sequester, on the border of 
 the abcess (arrow). One can see granulation tissue and sclerotic 
 bone tissue (block arrow).
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Figure 2: Example of locally treated osteomyelitis with gentamicin beads 
 enabling a high antibiotic tissue level at the site of infection.
Klemm followed suit with antibiotic bead chains for the treatment of chronic infection 
(Klemm, 1993). Subsequently biodegradable collagen ﬂ eeces appeared, which produced 
high local antibiotic concentrations (Ipsen et al., 1991). In contrast to biodegradable 
materials, PMMA-beads allow staged treatment and require surgical removal after each 
treatment episode. 
 Disadvantages of currently used non-biodegradable PMMA carriers include 
low antibiotic release by cements and the requirement of surgical removal in the case 
of PMMA-beads (Henry et al., 1995). Moreover, resistant bacteria may appear on the 
carrier surface during later stages of low-level antibiotic release (Neut et al., 2001). 
 In contrast, biodegradable antibiotic carriers may result in high release 
and obviate the need for removal; they are gradually replaced by in growing tissue 
(Walenkamp, 2001; Wichelhaus et al., 2001). Furthermore, secondary release of the 
antibiotic may occur during the degradation phase of the carrier, this could increase 
the antimicrobial efﬁ cacy compared to non-biodegradable carriers (Humphrey et al., 
1998).
Gentamicin in orthopaedic surgery
 Gentamicin has long been the primary choice of orthopaedic surgeons for 
prevention and local treatment of osteomyelitis (Marks et al., 1976; Walenkamp et al., 
1998). Gentamicin is a broad spectrum antibiotic, which is active against both Gram-
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positive and Gram-negative bacteria (Hill et al., 1977). The long-term release proﬁ les 
of gentamicin from PMMA and calcium phosphate cements have been demonstrated 
in kinetic release studies (Kanellakopoulou et al., 2000; Wahlig et al., 1978).Overall, 
the use of gentamicin-loaded PMMA beads results in high local antibiotic bone and soft 
tissue concentrations versus low systemic concentrations, thus reducing systemic side 
effects (Wahlig et al., 1978). On the contrary, a high systemic dosage of gentamicin 
needed to reach sufﬁ cient tissue penetration would create serious toxic side effects 
(Craig, 1995).
Antimicrobial resistance
 For many years classic antibiotics have been applied successfully to overcome 
bacterial infections. However, a number of studies have shown an increase in antibiotic-
resistant bacteria such as gentamicin-resistant S. aureus (GRSA) and methicilline-resistant 
S. aureus (MRSA) (von Eiff et al., 1997; Witte, 1999; Zetola et al., 2005). Prevalence 
of MRSA in nosocomial infections has exceeded even 30% in some countries, e.g. in 
southern Europe and the USA (Kac et al., 2000; Witte, 1999). Neut et al. demonstrated 
gentamicin-resistant staphylococci on retrieved gentamicin-loaded PMMA beads, raising 
concern about the efﬁ cacy of this treatment option (Neut et al., 2001). Furthermore, 
reports are now emerging of S. aureus being resistant to vancomycin, the ﬁ nal choice 
of antibiotic (Hiramatsu, 2001; Whitener et al., 2004). As current antibiotic therapy 
options are becoming limited for staphylococcal infections, there is an urgent need 
for new antimicrobial agents to combat these resistant pathogens having a strongly 
reduced capacity in evoking resistance (Norrby et al., 2005).
Antimicrobial peptides
 Antimicrobial peptides (AMPs) are a new and promising class of antimicrobial 
agents derived from naturally occurring peptides to which it is difﬁ cult for a microorganism 
to become resistant (Hancock, 1997). These peptides are found on epithelial surfaces, 
in secretion ﬂ uids, like saliva, and in inﬂ ammatory cells, like neutrophil’s, and thus form 
a ﬁ rst line of host defense as part of the innate immune system (Hancock, 2001; 
Zasloff, 2002). Furthermore, they are thought to have a diminished tendency to induce 
resistance because of the evolutionary difﬁ culty in changing bacterial membrane 
structure (ﬁ gure 3) (Hancock, 1997; Zasloff, 2002). 
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Figure 3A: The Dhvar-5 antimicrobial peptide is shown in an α-helical 
  conformation with the amino acid sequence in a one letter code 
  projected underneath (van ‘t Hof et al., 2001). Figure 3B: The 
  3-dimensional structure of hLF1-11 is shown in a ball and stick 
  model without side chains derived from the molecule of lactoferricin 
  (Chen et al., 2003). 
These AMPs do not interfere with cellular metabolism like the classic antibiotics, but 
due to their positive charge, disrupt negatively charged cellular membranes. These 
properties together with the antimicrobial activity against a broad variety of pathogens 
have made AMPs attractive candidates for antimicrobial drug development (van ‘t Hof 
et al., 2001).
 Dhvar-5 is such a promising antimicrobial peptide based on the amino acid 
composition of histatin-5, one of the antifungal peptides found in human saliva (tables 
1 and 2) (van ‘t Hof et al., 2001). It has been constructed synthetically of 14 amino 
acids to create a net positive charge at the C-terminus and a hydrophobic N-terminus 
(Ruissen et al., 2001; van ‘t Hof et al., 2001). This positive charge is presumed to play 
a crucial part in its antimicrobial activity (Helmerhorst et al., 1997), allowing it to disrupt 
and to penetrate the negatively charged microbial cell wall, and after cellular entrance it 
is targeted to intracellular organelles like mitochondria (Helmerhorst et al., 1999). The 
Dhvar-5 molecule has both fungicidal and bactericidal activity in vitro against among 
others MRSA (Lyaruu et al., 2000; Ruissen et al., 2001). 
 The N-terminal antimicrobial peptide human Lactoferrin 1-11 (hLF1-11) is also 
a promising antimicrobial agent (tables 1 and 2). This peptide is derived from the active 
domain of human lactoferrin (N-terminal amino acids 1-11) (Lupetti et al., 2000). hLF1-
hLF1-11
BA
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11 has a broad antimicrobial spectrum in vitro against both bacteria and fungi (Lupetti 
et al., 2000; Lupetti et al., 2003; Nibbering et al., 2001). Furthermore, Nibbering et al. 
demonstrated the efﬁ cacy of hLF1-11 in vivo, reducing the number of MRSA bacteria 
after systemic administration in the mouse thigh infection model (Nibbering et al., 
2001).
Table 1  In vivo results of several broad spectrum AMPs. Especially MRSA 
 and A. baumannii currently cause difﬁ cult to treat nosocomial 
 infections. 
AMP Micro-organisms Animals and models
hLF1-11
A. baumannii, C. albicans,
 E. coli,K. pneumoniae, 
MRSA, S. aureus
Mouse, rabbit
(Dijkshoorn et al., 2004; Faber et al., 
2005; Lupetti et al., 2002; Nibbering et al., 
2001; Stallmann et al., 2004)
Bone infection, muscle infection
Dhvar-5 MRSA
Rabbit
(Faber et al., 2004)
Bone infection
Novispirin G10 P. aeruginosa, K. pneumoniae
Mouse, rat
(Bartlett et al., 2003; Steinstraesser et al., 
2002)
Burn infection, Lung infection
Protegrin-1 C. albicans, P. aeruginosa, S. aureus, MRSA
Mouse, pig, rat
(Ceccarelli et al., 2001; Steinberg et al., 
1997; Steinstraesser et al., 2001)
Burn infection, wound infection
Table 2  The amino acid sequences (in a one letter code) of several 
 antimicrobial peptides. Positively charged amino acids are indicated 
 by bold typeface. Notice the asymmetrical distribution of positively 
 charged amino acids in the active peptides. Three dimensional 
 folding in vivo may enhance this asymmetry. When in contact with 
 bacteria, the positively charged peptides perforate the negatively 
 charged bacterial cell membrane. Cystatin-S is an inactive control 
 peptide used in several in vitro studies.
Peptide Structure
Cystatin-S 
(inactive peptide) SSSKEENRIIPGGIYDA
Dhvar5 LLLFLLKKRKKRKY
hLF1-11 GRRRRSVQWCA
Novispirin G10 KNLRRIIRKGIHIIKKYG
Protegrin-1 RGGRLCYCRRRFCVCVVGR
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Aim of this thesis
 In the light of antimicrobial resistance and the need for new antimicrobial 
agents (Norrby et al., 2005), the aim of the work in this thesis was to develop and 
investigate a carrier system for antimicrobial peptides. Our research efforts focussed 
on the efﬁ cacy both Dhvar-5 mixed with PMMA bone cement as well as hLF1-11 mixed 
with calcium phosphate bone cement. 
 We investigated the release characteristics of Dhvar-5 and gentamicin from 
custom-made PMMA beads in Chapters 2 and 3. In the literature, there are also reports 
on the limitations of admixing additives to PMMA bone cement, as this can adversely 
inﬂ uence the mechanical properties (Lautenschlager et al., 1976). Therefore in chapter 
4, we investigated the mechanical characteristics and micro-architecture of PMMA bone 
cement containing Dhvar-5, gentamicin or both. We then proceeded to investigate the 
efﬁ cacy of Dhvar-5 beads in a well established rabbit model of MRSA osteomyelitis, as 
described in Chapter 5.
 Additionally, Stallmann et al. simultaneously investigated the efﬁ cacy of 
calcium phosphate bone cements as carriers for hLF1-11 (table 1) (Stallmann et al., 
2003). Stallmann et al. also demonstrated the efﬁ cacy of hLF1-11 incorporated into 
calcium phosphate cement to prevent S. aureus osteomyelitis in rabbits (Stallmann 
et al., 2004). Therefore, the investigation described in Chapter 6 demonstrates the 
efﬁ cacy of treating chronic MRSA osteomyelitis in rabbits with hLF1-11 incorporated 
into calcium phosphate bone cement. In Chapter 7, the overall results of this study 
are discussed generally in relation to the literature. In addition, suggestions for future 
studies are presented. 
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Abstract
 Osteomyelitis is still a major cause of morbidity and remains a difﬁ cult 
complication to treat in orthopedic surgery. The treatment of choice is a combination of 
systemic and local antibiotics. The insertion of gentamicin-loaded polymethylmethacrylate 
(PMMA) beads into the bone results in high local concentrations of gentamicin and 
low systemic concentrations. However, the effectiveness of this treatment is being 
hampered by the emergence anti-microbial resistance. New anti-microbial agents are 
therefore needed. One new class of promising antibiotics are the anti-microbial peptides 
(AMPs). They are derived from natural human peptides and have a low tendency to 
induce anti-microbial resistance.
 Dhvar-5 is an anti-microbial peptide, consisting of 14 amino acids, and is 
based on a domain in histatin-5, which is found in human saliva. It has demonstrated 
bactericidal activity in vitro. In order to develop a new local treatment for osteomyelitis 
using Dhvar-5, we investigated its release from PMMA beads and its anti-microbial 
activity against a clinical isolate of methicillin-resistant Staphylococcus aureus (MRSA) 
before and after release from PMMA beads.
 Speciﬁ c amounts of Dhvar-5 were incorporated into PMMA mini beads, 
containing 120, 600 and 1200 μg of Dhvar-5, respectively. Dhvar-5 was released from 
the beads in all three groups. Total release from the 120 μg beads was 9 μg per bead 
after 7 days. However, the release per bead in the 600 and 1200 μg beads was far 
more, 416 and 1091 μg, respectively, over a 28-day period. After release, Dhvar-5 also 
retained its anti-microbial activity against MRSA.
 On the basis of these data we concluded that the amount of Dhvar-5 
release from PMMA beads is not proportional to the amount incorporated, instead, 
it demonstrated an exponential relationship to the amount of total peptide released. 
Furthermore, the released peptide remained biologically active against a clinical isolate 
of MRSA.
25
Release of the antimicrobial peptide Dhvar-5 from polymethyl methacrylate beads
Introduction
 
 Mixtures of antibiotics with the artiﬁ cial resin polymethylmethacrylate (PMMA) 
and antibiotics have been used for several decades to prevent or to treat orthopaedic 
infections (Buchholz et al., 1970). These mixtures are used as bone cements in primary 
total joint arthroplasty to reduce the initial incidence of infections (Buchholz et al., 1981; 
Josefsson et al., 1981; Josefsson et al., 1990; Josefsson et al., 1993). In addition, 
antibiotic-containing PMMA beads in combination with systemic antibiotics have been 
used extensively to treat osteomyelitis (Harle, 1980; Jenny et al., 1979; van ‘t Hof et 
al., 2001; Wahlig et al., 1978; Walenkamp et al., 1998).
 PMMA beads containing gentamicin have long been the primary choice for 
treating osteomyelitis (Kanellakopoulou et al., 2000; Marks et al., 1976; Walenkamp, 
1997; Hancock, 1997; Witte, 1999). Gentamicin is a broad spectrum antibiotic, which 
is active against both Gram-positive and Gram-negative bacteria (Hill et al., 1977). The 
exothermic polymerization process of the PMMA does not inﬂ uence the bioactivity of 
gentamicin (Wahlig et al., 1978). And, the long-term release proﬁ les of gentamicin from 
PMMA beads have been demonstrated in kinetic release studies. Overall, the use of 
gentamicin-loaded PMMA beads results in high local bone and soft tissue concentrations 
and low systemic concentrations, thus reducing systemic side effects (Wahlig et al., 
1978). On the contrary, a high systemic dosage of gentamicin needed to reach sufﬁ cient 
tissue penetration would create serious toxic side effects. 
 However, recent studies have shown an increase in antibiotic-resistant bacteria 
such as gentamicin-resistant Staphylococcus aureus (GRSA) and methicillin-resistant 
Staphylococcus aureus (MRSA) (Witte, 1999). Prevalence of MRSA in nosocomial 
infections has exceeded 30% in some countries e.g., Southern Europe and the US (Kac 
et al., 2000). In addition, amongst a broad variety of pathogens, there is a continuing 
shift towards antibiotic resistance (Witte, 1999). Neut et al. demonstrated staphylococci 
on retrieved gentamicin-loaded PMMA beads, raising concern about the efﬁ cacy of this 
treatment option (Neut et al., 2001).  As the current antibiotic therapy for osteomyelitis 
is becoming a serious medical problem, there is an urgent need for better anti-microbial 
agents.
 Anti-microbial peptides are a new and promising class of antibiotics derived 
from naturally occurring peptides (Hancock, 1997). As part of the innate immune 
system, these are found on epithelial surfaces, in secretion ﬂ uids and in neutrophils, and 
thus form a ﬁ rst line of host defense (Zasloff, 2002). Studies have shown that they have 
a low tendency to induce resistance because of the evolutionary difﬁ culty in changing 
bacterial membrane structure (Hancock, 1997; Zasloff, 2002).
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 Dhvar-5 is an experimental anti-microbial peptide based on the amino 
acid composition of histatin-5, which is an antifungal peptide found in human saliva 
(Helmerhorst et al., 1999). It is a synthetic 14-amino acid peptide that has a net positive 
charge at the C-terminus and a hydrophobic N-terminus (Ruissen et al., 2001; van ‘t Hof 
et al., 2001). This positive charge is presumed to play a crucial part in its antimicrobial 
activity (van ‘t Hof et al., 2001); allowing it to disrupt and to penetrate the negatively 
charged bacterial cell wall; and after cellular entrance it is targeted to intra-cellular 
organelles (Helmerhorst et al., 1999). The Dhvar-5 molecule has both fungicidal and 
bactericidal activity in vitro against among others MRSA (Lyaruu et al., 2000; Ruissen 
et al., 2001). 
 As the use of PMMA beads containing antibiotics is a successful approach 
to the treatment of osteomyelitis, the present investigation was performed in order 
to analyze the release characteristics of the Dhvar-5 anti-microbial peptide from pre-
hardened PMMA beads in vitro. Local administration of the anti-microbial peptide 
Dhvar-5 could create an alternative for the treatment of osteomyelitis. However, since 
release patterns of anti-microbial peptides from bone cements are not yet known, we 
investigated the release of the anti-microbial peptide Dhvar-5 from PMMA beads. 
Materials & Methods
The PMMA beads
 The Dhvar-5 anti-microbial peptide was commercially synthesized (UCB-
Bioproducts, Braine-l’Alleud, Belgium) and was available as a white freeze-dried 
amorphous powder. Exact amounts of Dhvar-5 were thoroughly mixed with one gram 
of 
Figure 1:  A chain of ten custom-made PMMA mini beads as used in this 
 study.
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cement powder (Osteopal®, Biomet Merck, Darmstadt, Germany). Hereafter, 0.5 gram 
of liquid monomer component was added to the cement powder and mixed to a paste. 
Individual components were cooled to 4 °C until the mixing procedure, which was done 
under sterile conditions. The obtained paste was subjected to a slight vacuum in a 
syringe for 5 seconds, and subsequently injected into a custom-made mould. After 
polymerization around a stainless steel wire (Ø 0.3 mm) for 20 minutes, a chain of ten 
beads could be retrieved (Figure 1), all with the same conﬁ guration and weight. The 
beads were stored at –20 °C until the release experiment. Three different amounts of 
Dhvar-5 were added to the co-polymer cement powder, with the following weight/weight 
percentage (w/w %) of the dry cement powder 0.5, 2.5 and 5.0%. After correction for 
evaporated monomer, the beads contained 120, 600 or 1200 μg Dhvar-5 anti-microbial 
peptide, respectively. In addition, a control group of PMMA beads were made without 
Dhvar-5. 
The release experiment and analysis
 Individual beads (n=10 per group) were placed in a 96 wells polystyrene 
microtiter plate. 150 μl of distilled H2O (release medium) was added and fully submerged 
the bead. The release medium was exchanged at preset times, 30 min, 1, 2, 4 hours, 
and hereafter every 24 hours continued for 28 days. During the interim periods the 96 
wells plate was sealed to prevent evaporation of release medium.
 The frequent exchange of the release medium in the initial stages of the 
experiment prevents the concentration of peptide rising to too high a level, resulting in 
an unacceptable reduction in concentration gradient between the bead and the elution 
ﬂ uid. In later stages of the release experiment the peptide release decreases, which 
allows for exchange of the release medium every 24 hours. 
 The experiment was performed at room temperature and under shaking 
conditions. Hereafter, the medium was stored in Eppendorf containers at –20 °C until 
analysis. Also a release experiment was conducted in which the pH was monitored, 
there was no change in the levels throughout the experiment. 
 The bicinchoninic acid (BCA) protein assay reagent kit (Pierce, Rockford, 
Illinois, USA) was used to measure the Dhvar-5 concentration in the release medium. This 
method detects the peptide present in the release medium. Serial dilutions of Dhvar-5 
were used as a reference on every extinction measurement. Extinction was measured at 
540 nm with a benchmark microplate reader and analyzed with the microplate manager 
software, version 5.1 (Bio Rad Laboratories, Hercules, California, USA). To correct 
for background extinction the control group measurements were subtracted from 
the experimental measurements. The detection limit of the BCA-assay is 5 μg/ml, in 
preceding experiments this was veriﬁ ed for the Dhvar-5 peptide. The volume of release 
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medium 150 μl enabled a detection limit of a 0.75 μg per bead. The accuracy of the 
assay ranges from 0.4 to 6.7% as calculated from the mean error of the true value, and 
the precision ranges from 3.8 to 7.0% as calculated from the coefﬁ cient of variance.
In a preceding experiment, we investigated the adhesion of Dhvar-5 to glass, polypropylene 
and polystyrene. A solution of Dhvar-5 was stored for 24 hrs the respective container 
and the concentration determined by capillary zone electrophoresis (CZE). Furthermore, 
another experiment was done in which the released peptide was analyzed by means of 
CZE for control of the integrity of the peptide. Also, stability of the Dhvar-5 peptide was 
analyzed by heating it to 120 °C for 20 minutes and by storing the stock solution for 26 
weeks at 37 °C, and subsequently an anti-microbial assay (described below) performed 
to evaluate its anti-microbial activity.
Anti-microbial assay
 Anti-microbial activity was analyzed by a modiﬁ ed killing assay as described by 
Helmerhorst (Helmerhorst et al., 1997). In short, a methicillin-resistant Staphylococcus 
aureus (MRSA) clinical isolate was used as the test organism. An overnight culture was 
washed 3 times in PBS and diluted to contain approximately 2 x 108 colony forming 
units (CfU)/ml. Of this suspension, 50 μl was added to serial dilution series of Dhvar-5 
and release media of day one in a 96-well culture plate to yield a ﬁ nal volume of 200 μl. 
After one hour of incubation under agitation at 37 °C, 25 μl was diluted 200-fold in PBS 
and the surviving bacteria determined by plating 25 μl on blood-agar plates. After 24 
hours of incubation at 37 °C the percentage of killing was determined by the following 
equation: [1 – (number of viable counts of sample / average number of counts in control 
samples)] x 100%, and the IC50 values were determined at the concentration at which 
50% of the MRSA inoculum survived. The IC50 values were compared to evaluate the 
anti-microbial activity of Dhvar-5 after release from the PMMA beads.
Statistical methods
 Variables were compared using a t-test for independent samples assuming 
unequal variances and one way analysis of variance. Differences were considered 
signiﬁ cant at P<0.05.
Results
 Individual beads were retrieved of the same size and conﬁ guration 3 x 5 mm 
(Figure 1) and weighed 33.8 ± 0.2 mg. The CZE data demonstrated not only a single 
peak throughout the release experiment but also no shift in peak position during the 
experiment (data not shown). Furthermore, the CZE analysis demonstrated no adhesion 
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of Dhvar-5 to glass, polypropylene and polystyrene. The Dhvar-5 peptide demonstrated 
not only identical antimicrobial activity after being heated to 120 °C for 20 minutes, but 
also after storage for 26 weeks at 37 °C (data not shown).
 The Dhvar-5 release patterns per group of beads are shown in Figure 2 and 
Figure 3a. The 120 μg Dhvar-5 bead (n=5) released 9 ± 4.7 μg per bead, corresponding 
to 7.5% of the incorporated peptide over a 7 day period. The 120 μg Dhvar-5 beads 
showed a signiﬁ cantly lower release (P < 0.00001) at every measurement point than 
both the 600 and 1200 μg Dhvar-5 beads. 
 
Figure 2:  Dhvar-5 release pattern for the 120 μg/bead group (values are a 
 mean ± SD) of ﬁ ve beads.
 The 600 μg Dhvar-5 beads (n=10) released 416 ± 56 μg over a 28 day period 
(Figure 3b) resulting in 70% of the incorporated anti-microbial peptide being released. 
Furthermore, at day 9 80% of the total release was reached. The 1200 μg Dhvar-5 
per bead group (n=10) released 1091 ± 80 μg Dhvar-5 over a 28 day period (Figure 
3b), 80% of the total release was reached at day 8. Furthermore, the 1200 μg Dhvar-5 
per bead group released 91% of the added anti-microbial peptide over the same 28 
day period. The 1200 μg Dhvar-5 beads released signiﬁ cantly more peptide over a 
28 day period (P < 0.00005). The 1200 μg bead highest release concentrations were 
measured at the ﬁ rst day being 1276 (± 146) μg/ml .
 The 600 μg and 1200 μg Dhvar-5 beads displayed similar release patterns, 
with an initial high release period during the ﬁ rst week, followed by a lower level of 
continued release. The release remains statistically higher for the 1200 μg Dhvar-5 
beads than for the 600μg beads until day 22, indicating that the 1200 μg beads have 
reached the completion of release at this day (Figure 3a). The same release proﬁ le was 
found in the 120 μg bead group. However, the experiment was terminated because the 
absolute release was below the detection of our protein assay (Figure 2).
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Figure 3a
Figure 3b
 Figure 3a shows the absolute Dhvar-5 release from the 600 and 
 1200 μg per bead, and Figure 3b the cumulative release proﬁ le 
 computed from the data in ﬁ gure 3a. The cumulative values of the 
 1200 μg/bead group were signiﬁ cantly higher than those of the 
 600 μg/bead group throughout the experiment (values are mean of 
 10 determinations ± SD from two different experiments).
 The results of the killing assay are shown in Figure 4. The released Dhvar-
5 peptide from the 600 μg and 1200 μg Dhvar-5 bead showed an IC50 value of 14.6 
± 6.8 μg/ml and 2.0 ± 1.1 μg/ml against MRSA, respectively, as compared to the 
reference dilution of Dhvar-5: 4.9 ± 0.5 μg/ml against MRSA. Furthermore there was no 
signiﬁ cant difference between the IC50 values of the released and reference solution of 
Dhvar-5.
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Figure 4:  Comparison of the MRSA killing activity between a stock solution of 
 Dhvar-5 peptide (reference peptide), and the released peptide 
 from the 600 and 1200 μg/bead groups. For these experiments the 
 peptide released on the ﬁ rst day was used. The anti-microbial 
 active range of Dhvar-5 against MRSA is 4.9 ± 0.5 μg/ml (IC50) in 
 vitro. Each measurement point is an average of 4 determinations.
Discussion
 Currently, the surgical treatment of osteomyelitis consists of a thorough 
debridement, usually followed by a temporary placement of gentamicin-containing 
PMMA beads (Harle, 1980; Walenkamp et al., 1998). However, emergence of resistant 
bacteria are starting to undermine the efﬁ cacy of this treatment option (Kac et al., 
2000; Waldvogel, 1999; Witte, 1999). To overcome these problems clinicians started 
to use alternative antibiotics, such as vancomycin mixed in manually made PMMA 
beads (Ozaki et al., 1998). But intermediate-vancomycin resistance is now emerging, 
prompting fears of loosing the last refuge for treating antibiotic-resistant bacteria (Denis 
et al., 2002; Waldvogel, 1999).
 Anti-microbial peptides are a new class of promising antimicrobial agents with 
a low tendency to induce resistance in vitro (Hancock, 1997; Zasloff, 2002). Also, 
clinical applications for anti-microbial peptides are currently under investigation, such 
as the saliva substitute xanthan loaded with anti-microbial peptides for treating oral 
candidosis (Ruissen et al., 1999). Furthermore phase II and III clinical trials have been 
conducted with the anti-microbial peptide rBPI21 to improve the clinical outcome of 
severe meningococcal sepsis (Giroir et al., 1997; Giroir et al., 2001). Van ‘t Hof et al. 
has reviewed the current anti-microbial peptides under clinical investigation (van ‘t Hof 
et al., 2001). 
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 The study presented demonstrates that the anti-microbial peptide Dhvar-5 is 
released from PMMA beads for a sustained period of time and Dhvar-5 retains its anti-
microbial activity after release (Figure 4). Also, quantity of the released peptide was 
dependent upon the amount of Dhvar-5 added to the cement. The release pattern of 
Dhvar-5 from the beads resembled the release pattern of gentamicin only in the 120 
μg (0.5 %w/w) Dhvar-5 beads (Kuhn, 2000; Wahlig et al., 1978). This resulted in 8% 
release of the incorporated Dhvar-5 (Figure 3b). However, when the amount of peptide 
added was increased to 600 μg (2.5% w/w) per bead, the amount of peptide released 
increased to 70% (Figure 3b). Furthermore, if the quantity was increased to 1200 μg 
(5.0% w/w), the released amount increased to 91% of incorporated Dhvar-5 (Figure 
3b). The percentages of released Dhvar-5 are far more than previously described in 
the literature for other antibiotics (Buchholz et al., 1970; Kuhn, 2000; Wahlig et al., 
1978).
 Known factors that inﬂ uence antibiotic release from PMMA are surface 
roughness and porosity (van de Belt et al., 2000). Van de Belt et al. demonstrated that 
porosity corresponded best with the eventual amount of release. The high amount of 
Dhvar-5 release that has been observed in this study may be explained by the structure 
of the peptide, a freeze-dried amorphous powder, which has a relatively high volume 
compared to gentamicin sulfate. It may be hypothesized that at higher concentrations of 
Dhvar-5, the peptide creates a porous network throughout the bead, allowing diffusion 
from the core of the bead. 
 Limitations of the study presented are the release conditions which could have 
simulated the in vivo conditions better. However, the release medium, dH2O was chosen 
because of its lack of protein, which enabled us to measure the release of Dhvar-5 with 
a BCA protein assay. Furthermore, from the literature it is known that physiological ionic 
conditions can inﬂ uence the activity of anti-microbial peptides (Helmerhorst et al. 1999), 
for reasons of comparison with other experiments using different peptides (unpublished 
data), the medium dH2O was used. Also the release temperature was not physiologic, 
though constant. We therefore conclude that the experiment was conducted under 
controlled conditions, rather than under physiological conditions.
 The presented data show that the anti-microbial peptide (Dhvar-5) release 
kinetics from PMMA bone cement is dependent upon the amount of peptide added: 
higher percentage of incorporation resulted in higher percentage of peptide released. 
Furthermore, Dhvar-5 retains its anti-microbial activity after release from the PMMA 
beads. Further investigations will focus on the efﬁ cacy of anti-microbial peptide-loaded 
PMMA beads in an in vivo osteomyelitis model and its micro-architectural structure.
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Simultaneous release of Dhvar-5 and 
gentamicin from PMMA beads
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The effect of the antimicrobial peptide, Dhvar-5, on gentamicin release 
from a polymethyl methacrylate bone cement. 
Christopher Faber, Roel J Hoogendoorn, DM Lyaruu, Hein P Stallmann, 
Jan van Marle, Arie van Nieuw Amerongen, Theo H Smit, Paul IJM Wuisman 
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Abstract
 The objective of this study was to investigate the release mechanism and 
kinetics of the antimicrobial peptide, Dhvar-5, both alone and in combination with 
gentamicin, from a standard commercial polymethyl methacrylate (PMMA) bone cement. 
Different amounts of Dhvar-5 were mixed with the bone cement powders of Osteopal 
and the gentamicin containing Osteopal G bone cement and their release kinetics from 
the polymerized cement were investigated. The total Dhvar-5 release reached 96% 
in the 100 mg Dhvar-5/g Osteopal cement, whereas total gentamicin release from 
Osteopal G reached only 18%. Total gentamicin release increased signiﬁ cantly to 67% 
with the addition of 50 mg Dhvar-5/g, but the Dhvar-5 release was not inﬂ uenced. The 
antimicrobial peptide Dhvar-5 signiﬁ cantly increased gentamicin release from PMMA 
beads.
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Introduction
 Admixture of antibiotics to polymethyl methacrylate (PMMA) bone cements has 
been used for several decades to prevent or to treat orthopaedic prosthesis infections 
(Buchholz et al., 1970; Josefsson et al., 1993). PMMA bone cements containing 
gentamicin have long been the primary choice of the orthopaedic surgeon (Buchholz 
et al., 1970). Gentamicin is a broad spectrum antibiotic, which is active against both 
Gram-positive and Gram-negative bacteria (Hill et al., 1977). However, several authors 
demonstrated gentamicin-resistant staphylococci in patients after using gentamicin-
containing bone cement (Sanzen et al., 1988; Tunney et al., 1998). The selection 
of resistant bacteria is thought to occur through the long-term low level release of 
gentamicin following the initial burst release (van de Belt et al., 1999). Several research 
efforts have been initiated towards modifying the release kinetics of antibiotics from 
PMMA bone cements (Frutos et al., 2002; Virto et al., 2003). Prolonging the initial 
burst release and possibly stopping the low level sustained release would prevent the 
selection of resistant bacteria (van de Belt et al., 1999).
 Another approach to address the problem of resistance is the admixture of new 
antimicrobial agents to PMMA bone cement (Faber et al., 2003). Antimicrobial peptides 
are a new and promising class of antibiotics derived from naturally occurring peptides 
(Hancock, 1997). As part of the innate immune system, they are found on epithelial 
surfaces, in secretion ﬂ uids and in neutrophils, and thus form a ﬁ rst line of host defense 
(Zasloff, 2002). Several studies have shown that these peptides are less likely to induce 
resistance than conventional antibiotics (Hancock, 1997; Zasloff, 2002). Dhvar-5 is an 
experimental antimicrobial peptide based on the amino acid composition of histatin-5, 
an antifungal peptide found in human saliva (Helmerhorst et al., 1999; Ruissen et al., 
2001; van ‘t Hof et al., 2001). The Dhvar-5 molecule has both antimicrobial activity in 
vitro and in vivo against methicylline-resistant Staphylococcus aureus (MRSA) (Faber et 
al., 2003; Faber et al., 2004; Lyaruu et al., 2000).
 A previous release study showed that approximately 70% of the Dhvar-5 
was released from PMMA bone cement (Faber et al., 2003). This Dhvar-5 release was 
substantially higher than that reported for gentamicin release from PMMA (Buchholz 
et al., 1970; van de Belt et al., 2000; Wahlig et al., 1978). Therefore we wanted 
to investigate whether the addition of Dhvar-5 to gentamicin containing bone cement 
would inﬂ uence gentamicin release.
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Materials and Methods
Sample preparation
 The beads were prepared in the same manner as described before (Faber et 
al., 2003). In short, the antimicrobial peptide, Dhvar-5 was made by solid-phase peptide 
synthesis using Fmoc (9-ﬂ uorenyl-methoxycarbonyl) chemistry as described previously 
(Van’t Hof et al., 1993), and was available as a white freeze-dried amorphous powder. 
Exact amounts of Dhvar-5 were thoroughly mixed with the PMMA cement powder 
(Table 1), either Osteopal® or gentamicin-containing cement, Osteopal G® (Biomet 
Merck, Darmstadt, Germany). Hereafter, the liquid monomer component was added 
to the cement powder and mixed to a paste (liquid-to-powder ratio, 1:2). Individual 
components were pre-cooled to 4 °C until the mixing procedure, which was done under 
sterile conditions. The obtained paste was subjected to a slight vacuum in a syringe 
for 5 seconds, and subsequently injected into a custom-made mould to create the mini 
beads.
Table 1
Abbreviation
cAdditives
(mg/g cement powder)
a Osteopal No additive
a Ost-25 25 mg Dhvar-5
a Ost-50 50 mg Dhvar-5
a Ost-100 100 mg Dhvar-5
b OstG 25 mg gentamicin
b OstG-25 25 mg gentamicin, 25 mg Dhvar-5
b OstG-50 25 mg gentamicin,50 mg Dhvar-5
aOsteopal is a plain bone cement and bOsteopal G has 25 mg gentamicin /g cement powder (Biomet Merck 
GmbH, Darmstadt, Germany), both bone cements are commercially available and are identical except for the 
gentamicin content in Osteopal G.
cOther standard constituents, e.g. the zirconium dioxide, chlorophyll, etc. are not mentioned here and were the 
same for all cement mixtures.
The custom-made PMMA mini beads, the paste was polymerized around a stainless 
steel wire (∅ 0.3 mm) to create a chain of ten beads, all with the same conﬁ guration (3 
× 5 mm) and weight (± 33 mg). 
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Elution assay
 The release was examined as described before (Faber et al., 2003). In short, 
individual beads were placed in a 96-wells polystyrene microtiter plate. 200 μl of release 
medium (distilled H2O) was added to fully submerge the bead. The release medium was 
subsequently exchanged at preset times, 30 min, 1, 2, 4, 24 hours, and hereafter every 
24 hours continued for 28 days. Release medium was exchanged more frequently at 
the onset of the experiment to prevent possible saturation by the initial burst release. 
The experiment was performed at ambient temperature, under shaking conditions, and 
during the interim periods the wells were sealed to prevent evaporation. The collected 
medium was stored at –20 °C until analysis. A bicinchoninic acid (BCA) protein assay 
(Pierce, Rockford, Illinois, USA) was used to measure the Dhvar-5 concentration 
in the release medium (Faber et al., 2003; Stallmann et al., 2003). The gentamicin 
concentrations were measured using an AxSym System (Abott Laboratories, Irving, TX, 
US) (van de Belt et al., 2000).
Statistical methods
 The data were analysed using the Statistical Package for the Social Sciences 
(SPSS) version 10.1 for Windows. Release variables a were analyzed by one-way 
analysis of variance (ANOVA) with the Bonferroni post hoc test. Differences between 
groups were considered signiﬁ cant at p < 0.05.
Results
 As expected, the Ost-100 group (n = 4) had signiﬁ cantly higher release of 
Dhvar-5 than the other groups at all time points (p < 0.0001) (see Figure 1). The Ost-50 
(n = 6) and the Osteopal G + 50 mg/g (OstG-50) (n = 6) groups initially had the same 
release at day one and two (p = 0.3 and p = 0.06), however at day ﬁ ve release of Dhvar-
5 becomes signiﬁ cantly higher in the OstG-50 group (p < 0.0001). From day 14 to 28 
release in both groups was the same again. The Osteopal + 25mg/g (Ost-25) (n = 6) 
and Osteopal G + 25 mg/g (OstG-25) (n = 4) group have the same Dhvar-5 release at all 
time points. The Dhvar-5 release in the Ost-25 and OstG-25 groups is also signiﬁ cantly 
lower compared to all other groups at all time points (p < 0.0001). 
 Initial gentamicin release at day one is signiﬁ cantly higher in the OstG-50 (n 
= 6) group compared to the Osteopal G (OstG) group, p = 0.006 (Figure 2). Neither 
the difference between OstG (n = 9) and OstG-25 (n = 4) groups nor between OstG-25 
and OstG-50 groups reaches signiﬁ cance at day one. At day two however, gentamicin 
release for both the OstG-25 and OstG-50 groups was signiﬁ cantly higher than the 
OstG group (p = 0.036 an p = 0.0004, respectively). From day six through day 21, 
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Figure 1: Release of Dhvar-5 from PMMA mini beads (mean ± SD), the 
 release data of the ﬁ rst 24 hrs are pooled to give one data point. 
 The Ost-100 group (n = 4) has the highest release of Dhvar-5, 
 followed by the Ost-50 (n = 6) and the OstG-50 (n = 6) groups, 
 with only minor differences. The Ost-25 (n = 6) and OstG-25 (n = 4) 
 groups showed the lowest Dhvar-5 release, both groups had the 
 same release at all time points. The insert shows the cumulative 
 release curves of Dhvar-5 plotted against time. Neither the 
 difference in Dhvar-5 release between the Ost-25 and OstG-25 
 groups nor between the Ost-50 and OstG-50 groups are signiﬁ cant 
 at any time point. However, the differences in Dhvar-5 release 
 between Ost-25, Ost-50 and Ost-100 are highly signiﬁ cant (p < 
 0.01), as are the differences between OstG-25 and OstG-50 (p < 
 0.01) for all time points. 
the gentamicin release of both the OstG-25 and OstG-50 groups are not statistically 
different. The release for these two groups remains signiﬁ cantly higher than the OstG 
group until day 21. At day 28 only the OstG-25 group has signiﬁ cantly higher release 
than the OstG group (p = 0.01).
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Figure 2: Gentamicin release from PMMA mini beads containing gentamicin 
 and/or Dhvar-5. The release data of the ﬁ rst day are pooled to give 
 one data point. Gentamicin release is signiﬁ cantly higher in the 
 OstG-50 (n = 6) group compared to the OstG group at all time points. 
 And, from day 2 to 28 the gentamicin release of both the OstG-25 
 and OstG-50 groups are signiﬁ cantly higher than the OstG group. 
 From day six through to day 21 the gentamicin release of both the 
 OstG-25 and Ost-50 groups are not statistically different. The insert 
 shows cumulative release curves of gentamicin. The cumulative 
 gentamicin release is signiﬁ cantly increased from day 1 to day 28 
 in both the OstG-25 and the OstG-50 group compared to the OstG 
 group, p = 0.02 and p = 0.01 respectively. The cumulative gentamicin 
 release is not statistically different between the OstG-25 and OstG-
 50 group at any time point. 
The percentage of Dhvar-5 release increased with higher levels of peptide content; 
61%, 72% and 96% of the incorporated Dhvar-5 were released for the Ost-25, Ost-50 
and Ost-100 groups, respectively. Neither the total amount of Dhvar-5 release nor the 
release curves were signiﬁ cantly inﬂ uenced by the presence of gentamicin in the PMMA 
matrix. The OstG-25 and OstG-50 groups released 57% and 81%, respectively, of the 
incorporated Dhvar-5. By contrast, the total gentamicin release increased signiﬁ cantly 
with the admixture of Dhvar-5, from 18% in the OstG group to 59% and 67% in the OstG-
25 and OstG-50 groups of the incorporated gentamicin, respectively. The gentamicin 
release was signiﬁ cantly increased from day 2 to 21 in both the OstG-25 and OstG-50 
groups compared to the OstG group. 
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Discussion
The data presented in this study conﬁ rms the results of our previous study that the 
admixture of Dhvar-5 to PMMA bone cement results in a very high concentration 
dependent release, even up to 96% in the Ost-100 group (ﬁ gure 1) (Faber et al., 2003). 
The gentamicin release is consistent with the quantity of release described by Kuhn for 
the Ost-G bone cement, thereby further verifying our release model (Kuhn, 2000). 
 The addition of Dhvar-5 to the OstG bone cement signiﬁ cantly increased 
gentamicin release by a fourfold. This increase in gentamicin release, however, was 
not dependent on the amount of added Dhvar-5 (ﬁ gure 2). This ﬁ nding suggests that 
the addition of 25 mg of Dhvar-5/g to Ost-G bone cement is sufﬁ cient to increase the 
porosity resulting in fourfold increase of gentamicin release as apposed to the OstG-50 
cement. Furthermore, the quick drop in gentamicin release seen in the OstG cement, 
is transformed into a more gradual decline in gentamicin release in the OstG-25 and 
OstG-50 cement. This ﬁ nding also suggested a porous network which would allow for 
gentamicin crystals to also dissolve from deeper layers of the PMMA bone cement. On 
the other hand, the Dhvar-5 release was not inﬂ uenced by admixing gentamicin (ﬁ gure 
1). Virto et al. investigated the effect of adding lactose or hydroxypropylmethylcellulose 
(HPMC) to gentamicin containing cement (Virto et al., 2003). Interestingly, they also 
found a four-fold increase in gentamicin release with lactose as opposed to HPMC. 
They hypothesized that the increase in release was due to dissolution of the hydrophyllic 
lacose. Our data suggest a similar mechanism of increased porosity by the dissolution 
of Dhvar-5, resulting in a signiﬁ cant increase in release of gentamicin.
 Factors that inﬂ uence antibiotic release from PMMA bone cement are surface 
roughness and porosity (van de Belt et al., 2000). Van de Belt found that porosity 
corresponded best with increased gentamicin release from commercially available bone 
cements. The high amount of Dhvar-5 release and concordant increase in gentamicin 
release by the addition of this AMP to the Osteopal® bone cement further supports 
the hypothesis that Dhvar-5 creates a porous network allowing for diffusion of both 
antibiotics from the core of the bead. To test this hypothesis ultrastructural studies have 
been performed and are described in chapter 4 of this thesis. 
 The data presented show that the addition of 25 mg/g Dhvar-5 to Osteopal 
G bone cement results in a fourfold increase of gentamicin release. This increase in 
gentamicin release does not appear to be Dhvar-5 concentration dependent. On the 
other hand, the addition of gentamicin does not inﬂ uence the Dhvar-5 release proﬁ le. 
Further studies are needed to elucidate the mechanism of release.
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Abstract
 The objective of this study was to investigate the micro-architectural properties 
and mechanical properties of a standard commercial polymethyl methacrylate (PMMA) 
bone cement containing different amounts of the antimicrobial peptide Dhvar-5 and 
gentamicin. The secondary aim was to elucidate the previously found fourfold increase 
in gentamicin release with the addition of Dhvar-5 to a gentamicin containing PMMA 
bone cement. Different amounts of Dhvar-5 were mixed with the bone cement powders 
of Osteopal and the gentamicin-containing Osteopal G bone cement. The internal 
structure of the bone cements were analyzed by scanning electron microscopy (SEM) 
of the fracture surfaces. Secondly, porosity was investigated with the mercury intrusion 
method and related to previously observed release proﬁles. In order to obtain an insight 
into the mechanical characteristics of the bone cement mixtures, the compressive 
strength of Osteopal and Osteopal G with Dhvar-5 was also investigated. SEM showed 
an increase of dissolved gentamicin crystals with the addition of Dhvar-5. The mercury 
intrusion results suggested an increase of small pores (<0.1 μm) with the addition of 
Dhvar-5. Compressive strength of Osteopal was reduced by the addition of Dhvar-5 and 
gentamicin, but still remained above the limit prescribed by the ISO standard for clinical 
bone cements. We therefore conclude that the antimicrobial peptide Dhvar-5, when 
used together with gentamicin sulphate, made the gentamicin crystals more accessible 
for the release medium presumably through increased micro-porosity (<0.1 μm).
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Introduction
 Previous release studies showed that approximately 70% of the Dhvar-5 
was released from PMMA bone cement (Faber et al., 2003). This Dhvar-5 release was 
substantially higher than that reported for gentamicin release from PMMA (Buchholz 
et al., 1970; van de Belt et al., 2000; Wahlig et al., 1978). Furthermore, the addition 
of Dhvar-5 to commercially available bone cement Osteopal G increased gentamicin 
release fourfold (Faber et al., 2005). Van de Belt et al. showed that gentamicin release 
was related to PMMA porosity, and to a lesser extent, to the surface roughness and 
wettability (van de Belt et al., 2000). We therefore hypothesized that the addition of 
Dhvar-5 antimicrobial peptide creates a porous network through the PMMA cement 
allowing almost complete release of this substance from the PMMA matrix (Faber et al., 
2003).
 In this study we investigated whether Dhvar-5 creates a porous network in 
the PMMA matrix. Therefore, we admixed Dhvar-5 to gentamicin-containing PMMA bone 
cement. The internal structure of the PMMA bone cement mixtures were analysed by 
scanning electron microscopy (SEM) and porosity was investigated by the mercury 
intrusion method (Virto et al., 2003). 
 In the literature, there are also reports on the limitations of admixing additives 
to PMMA bone cement, as this can adversely inﬂ uence the mechanical properties 
(Lautenschlager et al., 1976). If the mechanical properties are not adequate, the 
application of Dhvar-5 in PMMA bone cement would be limited to the use in non-load 
bearing applications. In this study, we therefore also investigated the inﬂ uence of Dhvar-
5 on the compressive strength of PMMA bone cement.
Materials and methods
Sample preparation
 The beads were prepared in the same manner as described previously 
(Faber et al., 2003). In short, the anti-microbial peptide, Dhvar-5 was made by solid-
phase peptide synthesis using Fmoc (9-ﬂ uorenyl-methoxycarbonyl) chemistry as 
described previously (van’t Hof et al., 1993), and was available as a white freeze-dried 
amorphous powder. Exact amounts of Dhvar-5 were thoroughly mixed with the PMMA 
cement powder (Table 1), either Osteopal® or gentamicin-containing cement, Osteopal 
G® (Biomet Merck, Darmstadt, Germany). Hereafter, the liquid monomer component 
was added to the cement powder and mixed to a paste (liquid-to-powder ratio, 1:2). 
Individual components were pre-cooled to 4 °C until the mixing procedure, which was 
done under sterile conditions. The obtained paste was subjected to a slight vacuum in a 
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syringe for 5 seconds, and subsequently injected into different custom-made moulds to 
create either beads for SEM and elution studies or cylinders for compressive strength 
testing.
 For the preparation of the custom-made PMMA mini-beads, the paste was 
polymerized around a stainless steel wire (∅ 0.3 mm) to create a chain of ten beads, 
all with the same conﬁ guration (3 × 5 mm) and weight (± 33 mg). The preparation of 
the compressive strength samples was exactly the same, the only difference being 
that the cement paste was injected into a metal mould as prescribed in Annex E of 
the ISO standard 5833. The obtained cylinders (∅ 6 mm, 12 mm length) were stored 
for exactly eight days at ambient temperature before compressive strength testing, to 
allow for residual polymerization and monomer evaporation.
Elution assay
 The release was examined as described before (Faber et al., 2003). In short, 
individual beads were placed in a 96-wells polystyrene microtiter plate. 200 μl of release 
medium (distilled H2O) was added to fully submerge the bead. The release medium was 
subsequently exchanged at preset times, 30 min, 1, 2, 4, 24 hours, and hereafter 
every 24 hours continued for 28 days. The experiment was performed at ambient 
temperature, under shaking conditions, and during the interim periods the wells were 
sealed to prevent evaporation. 
Scanning Electron Microscopy (SEM)
 After the release experiment, the beads were stored at ambient temperature 
in the dark. To investigate the internal structure of a specimen, they were cooled in liquid 
nitrogen and broken in a custom made device. Cooling avoided plastic deformation at 
ambient temperature. Specimens were sputter-coated with gold and imaged with a 
Philips SEM525 scanning electron microscope. 
Mercury intrusion method
 The porosity of the cement samples was determined by the mercury intrusion 
porosimetry (Micrometrics Pore Sizer9220, Norcross, GA, USA) (Virto et al., 2003). The 
beads were ﬁ rst allowed to elude their antibiotics for 28 days as described above. Prior 
to analyses, the specimens are vacuum degassed, to remove all possible moisture. 
The pressure is gradually increased to 55,000 psia (pounds per square inch, absolute) 
whilst the intrusion volume is being recorded. The total open porosity was calculated 
from the total intrusion volume and pore size was calculated from the Wasburn equation 
(Virto et al., 2003). 
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 To obtain sufﬁ cient cement volume, a minimum of 14 beads per group were 
analysed simultaneously in one measurement. One bead would have insufﬁ cient volume 
to allow for a reliable measurement. Unfortunately, the large number of required beads 
also precluded the possibility of repeated measurements, as the cost of custom-made 
peptide production and the mercury intrusion method are very high.
Table 1  PMMA bone cement mixtures analyzed and their abbreviations. 
 The porosity and median pore size are given as determined by the 
 mercury intrusion method after an elution period of 28 days.
Abbreviation
cAdditives
(mg/g cement 
powder)
Median pore 
diameter (nm) Open Porosity %
a Osteopal No additive 14.8 7.8
a Ost-25 25 mg Dhvar-5 15.1 8.4
a Ost-50 50 mg Dhvar-5 17.4 9.0
b OstG 25 mg gentamicin 15.1 9.9
b OstG-25
25 mg gentamicin, 
25 mg Dhvar-5 16.2 12.1
b OstG-50
25 mg gentamicin,
50 mg Dhvar-5 34.3 15.4
aOsteopal is the plain bone cement and bOsteopal G containes 25mg gentamicin /g cement powder 
(Biomet Merck GmbH, Darmstadt, Germany). Both bone cements are commercially available and 
are identical except for the gentamicin content in Osteopal G.
cOther standard constituents, e.g. the zirconium dioxide, chlorophyll, etc. are not mentioned here 
and were the same for all cement mixtures.
Compressive strength
 Two groups, 50 mg (Ost-50) (n=5) and 100 mg Dhvar-5 (Ost-100) (n=5) /g 
of cement powder (Osteopal®, Biomet Merck GmbH, Darmstadt, Germany) containing 
Dhvar-5 only were analysed for compressive strength. Plain bone cement samples were 
prepared as controls (n=5) (Table 1). Additionally, the commercially available bone 
cement Osteopal G (OstG) (n=6) (Biomet Merck GmbH, Darmstadt, Germany) containing 
25 mg gentamicin/g dry cement powder was analysed for compressive strength alone 
and with different quantities of admixed Dhvar-5, 25 mg (OstG-25) (n=7) and 50 mg 
Dhvar-5 (OstG-50) (n=7) /g of cement powder, respectively. Compressive strength 
testing was performed as described in Annex E of the ISO standard 5833.
 In short, samples were discarded if large air bubbles (∅ > 1 mm) were 
seen on a standard radiograph. Additionally, the diameters were determined in two 
perpendicular directions of two sections for estimation of the exact surface area. The 
samples were subjected to a compressive force at ambient temperature in an Instron 
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8872 universal testing machine (Instron, Norwood, MA, USA) with a cross-head speed 
of 20 mm/min. During the tests the load and the displacement were registered. From 
these data, the stress and the strain values of the test samples were calculated and 
plotted against each other. The force needed to cause either fracture, 2% offset load, 
or the upper yield-load point were registered; whichever occurred ﬁ rst was deﬁ ned as 
the yield point of the test sample.
Statistical methods
 The data were analysed using the Statistical Package for the Social Sciences 
(SPSS) version 10.1 for Windows. The compressive strength variables were analysed 
by  one-way analysis of variance (ANOVA) with the Bonferroni post hoc test. Differences 
between groups were considered signiﬁ cant at p < 0.05.
Results
Scanning electron microscopy
 The Dhvar-5 powder was a white amorphous powder with a very ﬂ uffy and 
fragile consistency, whereas the gentamicin sulphate consisted of large solid crystals 
(Figure 1). The two PMMA powders had the familiar appearance with pre-formed PMMA 
spheres and interspersed zirconium dioxide particles. As expected, the large gentamicin 
sulphate crystals were seen only in the OstG cement powder.
 The Dhvar-5 particles could not be visualised by SEM in the PMMA matrix. 
The fracture surface does become more irregular with increasing quantities of admixed 
Dhvar-5 (Figure 2). Admixing 50 mg Dhvar-5/g cement powder seems to interfere with 
the polymerisation process, which is reﬂ ected in the fracture pattern. The fracture seems 
to occur around the pre-formed PMMA spheres rather than through these spheres as in 
the cement containing less or no Dhvar-5 at all. The fracturing around the pre-formed 
spheres is also more pronounced closer to the surface of the bead, suggesting a 
different polymerisation of the surface as apposed to the core of the bead.
 The gentamicin crystals could be easily identiﬁ ed in the matrix. Empty imprints 
of dissolved gentamicin crystals are occasionally seen in direct contact with the surface 
of the OstG cement. The addition of Dhvar-5 to the cement seems to increase the 
number of empty imprints from dissolved gentamicin crystals, these empty imprints 
are more prominent closer to the surface of the beads. Although more prominent, the 
empty imprints were not in direct contact with the surface, suggesting a porous network 
that allows for dissolution of these gentamicin crystals. Also, the same increase in 
irregularities of the fracture surfaces are seen with increasing content of Dhvar-5 in the 
OstG cement as seen in the cement containing only Dhvar-5.
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 The outer surfaces of the beads showed slight changes in roughness with the 
admixture of Dhvar-5 (data not shown). This was most pronounced in the Ost-50 and the 
OstG-50 groups, showing a slightly more irregular surface as opposed to the groups 
with 25 mg or no admixed Dhvar-5. 
Figure 1A-D: SEM micro-photographs of the materials used in this study 
 (bars=100μm). Fig. 1A Dhvar-5 powder, note the fragile structure 
 of the amorphous powder, the insert emphasizes the fragility of 
 the powder (bar = 10 μm). Fig. 1B Gentamicin sulphate 
 powder has a crystalline structure, 60-220 μm grain size 
 (according to the manufacturer). Fig. 1C Powder of the plain 
 PMMA cement (Osteopal), the pre-formed PMMA spheres are 
 visible with interspersed much smaller zirconium dioxide 
 particles. Fig. 1D Powder of the gentamicin-containing cement, 
 a large gentamicin crystal (± 200 μm) can be seen amidst the 
 PMMA spheres and the zirconium oxide particles.
B
C D
A
54
Chapter 4
Figure 2 A - F;  Representative SEM micrographs from the fracture surfaces 
 of the different cement samples after 28 days release (bars 
 = 100 μm). The plain Osteopal (Fig. 2A) has a smooth 
 fracture surface. The arrow shows a zirconium oxide particle 
 imbedded in the PMMA matrix. The Osteopal G (Fig. 2B) also 
 has a smooth fracture surface and the gentamicin crystals 
 (solid block arrows) can be seen embedded in the PMMA 
 matrix and again zirconium particles can be seen (arrows). 
 The insert shows the imprint of a dissolved gentamicin 
 crystal after washing of the fracture surface. These empty 
 imprints were only observed in direct contact with the 
 surface in the OstG beads after 28 days release.
 The 25 mg Dhvar-5/g (Fig. 2C) also has a smooth fracture 
 surface and the same structures can be seen as in the plain 
 PMMA cement. The Dhvar-5 is not visible as apposed to the 
A B
C
E
D
F
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 gentamicin in the OstG cement. Raising the Dhvar-5 
 content to 50 mg/g (Fig. 2E) changes the fracture surface 
 of the cement. The fracture surface is not smooth as in the 
 plain bone cement, but has an irregular appearance. Again 
 no structure can be identiﬁ ed as remnants of the 
 antimicrobial peptide Dhvar-5. 
 In the gentamicin-containing cement with 25 mg Dhvar-
 5/g added (Fig. 2D) empty gentamicin voids were seen 
 near the edge of the bead, suggesting a dissolved gentamicin 
 particle (frame arrows) in the release experiment. However, 
 gentamicin particles were still present after the elution 
 assay (insert). The fracture surface still has a smooth 
 appearance as in the Ost-25 bead. In contrast, the OstG-
 50 group (Fig. 2F) has a much more irregular fracture 
 surface and seems to fracture around the pre-formed PMMA 
 spheres rather than through them. The fracture surface is 
 more irregular near the surface of the bead than towards 
 the middle. Also empty voids (frame arrows) are observed 
 near the surface, whereas gentamicin particles (solid block 
 arrows) are seen more towards the core of the bead. In 
 both the OstG-25 and OstG-50 group no structures could be 
 identiﬁ ed as the antimicrobial peptide Dhvar-5.
Mercury intrusion
 The addition of Dhvar-5 increased the porosity, however the admixing of 
gentamicin increases the porosity even more (see Table 1 and Figure 3). The incremental 
mercury intrusion shows that in all cement mixtures most of the porosity is caused by 
very small pores (< 0.1 μm) (see Figure 3).
 There are relatively few pores in the range 0.1 to 10 μm, and in the range of 
10 to 100 μm there are again a few large pores (Figure 3). Also, there is an increase 
in small pores (< 0.1 μm) with the addition of Dhvar-5 to Osteopal (Figures 3A, C and 
E) and this is reﬂ ected in an increase in the median pore size (Table 1). Similarly, this 
increase was more dramatically with the addition of Dhvar-5 to Osteopal G cement 
(Figure 3B, D and F) and is again reﬂ ected in the increased median pore size. In the 
OstG-50 cement there also seems to be an increase in pores between 0.1 and 1 μm.
 The OstG cement also showed a slightly higher intrusion volume at the small 
pore size (< 0.1 μm) than the Osteopal cement. All the cement mixtures with gentamicin 
showed ‘ink well’ pores (larger void with small opening) in their mercury intrusion 
measurements, these ‘ink well’ pores were more pronounced with increased content of 
Dhvar-5.
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Figure 3 A - F  Incremental intrusion volume of mercury vs. pore diameter 
 of bone cement mixtures after elution for 28 days. The arrows 
 point out large increases of intrusion volume with the same 
 pore size, the so-called ‘ink well’ pores.
 Fig. A) Osteopal, Fig. B) OstG, Fig. C) Ost-25, Fig. D) OstG-25, 
 Fig. E) Ost-50 and Fig. F) OstG-50.
Compressive strength
 The compressive strength of Osteopal (93 MPa) was clearly inﬂ uenced by 
the addition of Dhvar-5 (see Figure 4). Addition of 50 mg/g cement powder reduced 
the compressive strength by 6% (p = 0.004). Increasing the amount of admixed Dhvar-
5 to 100 mg/g cement powder further reduced the compressive strength by 17% 
compared to plain PMMA bone cement (p < 0.0001). The difference between Ost-50 
and Ost-100 is also signiﬁ cant, p < 0.0001. The compressive strength of OstG bone 
cement (84 MPa) is signiﬁ cantly lower compared to Osteopal (p < 0.0001). However, 
the compressive strength is not signiﬁ cantly reduced further by the addition of 25 or 
50 mg Dhvar-5/g cement. Despite the signiﬁ cant reduction in compressive strength by 
admixing Dhvar-5 or gentamicin, the compressive strength of all cement mixtures still 
remained substantially higher than the minimum requirement of the ISO 5833 standard 
(70 MPa), 87, 77, 81 and 82 MPa for the Ost-50, Ost-100, OstG-25 and OstG-50 
groups, respectively.
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Figure 4:  The compressive strength (mean ± SD) as determined by the ISO 
 5833 standard method. The addition of Dhvar-5 decreased the 
 compressive strength signiﬁ cantly compared to plain cement, p = 
 0.004 and p < 0.0001 for Ost-50 and Ost-100, respectively. The 
 compressive strength of the OstG cement was signiﬁ cantly lower 
 than the plain Osteopal cement (p < 0.0001) However compressive 
 strength was not signiﬁ cantly reduced further in the OstG-25 and 
 OstG-50 groups, p = 0.4 and p = 0.5, respectively. All samples tested 
 did meet the minimal requirements of the ISO 5833 standard (dotted 
 line = 70 MPa ).
Discussion
 The data presented in this study show that the admixture of Dhvar-5 resulted 
in a slight increase in micro-porosity as measured by the mercury intrusion method. This 
was also reﬂ ected in the altered fracture pattern of the Ost-50 group seen under the 
SEM.
 The gentamicin sulphate crystals are relatively large solid particles (60-220 
μm), which are present as separate entities inside the PMMA matrix. By contrast, the 
Dhvar-5 powder has completely different properties, being rather ﬂ uffy and fragile it 
brakes down into very small particles during mixing with the PMMA cement powder. 
Dhvar-5 could not be identiﬁ ed inside the PMMA matrix on the SEM micrographs.
 In the OstG bone cement gentamicin crystals were still present after 28 days 
of release, whereas with the admixture of Dhvar-5 more empty imprints of dissolved 
gentamicin crystals were seen. The empty imprints were more pronounced towards the 
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border of the beads, suggesting that Dhvar-5 facilitated the dissolution of the gentamicin 
crystals. Though the SEM micrographs suggested a more porous cement structure, the 
actual pores were difﬁ cult to visualize or quantify.
 In order to quantify the porosity of the different cement mixtures mercury 
intrusion measurements were performed. These measurements conﬁ rmed that the 
addition of Dhvar-5 increased open porosity of both the Osteopal and the OstG cement. 
Interestingly, the increase in porosity was mainly due to very small pores (< 0.1 μm). 
The difference in release of Dhvar-5 between the Ost-25 and Ost-50 bone cements 
cannot be fully explained by the minor increase in porosity between these groups, 8.4 
and 9.0%, respectively. The mercury intrusion data therefore suggest that pores are 
formed beyond the range of the mercury intrusion method (Mehta et al., 2000; Virto 
et al., 2003). The mercury intrusion data also shows that in the gentamicin containing 
cements with Dhvar-5, there were large intrusion volumes with the same small pore 
sizes (< 0.1 μm). This ﬁ nding suggests that larger voids are being ﬁ lled with mercury 
through a smaller opening, the so-called ‘ink well’ pores. These larger voids are most 
likely imprints of dissolved gentamicin sulphate crystals, as they were not seen in the 
groups without gentamicin.
 Virto et al. also found ‘ink well’ pores in cement containing gentamicin and 
lactose (Virto et al., 2003). In this respect, the results of our study corroborate the 
results of Virto et al. The data suggests that, like lactose, Dhvar-5 creates a porous 
network throughout the PMMA matrix allowing for enhaced release of both Dhvar-5 and 
gentamicin from deeper layers within the PMMA cement matrix.
 In the literature, several mechanisms for the release of gentamicin from 
PMMA have been proposed. Van de Belt et al. demonstrated that surface roughness is 
related to the initial burst release and that increased porosity of the matrix increases 
bulk gentamicin release from PMMA bone cement (van de Belt et al., 2000). Similarly 
Frutos et al. proposed a model of gentamicin release which divides release into three 
separate phases from their modiﬁ ed commercial PMMA bone cement (Frutos et al., 
2002); initial wash off form the surface; subsequent dissolution of gentamicin particles 
at the surface; and ﬁ nally diffusion of gentamicin through cracks and pores. 
 In our study, the data suggest that Dhvar-5 creates a small, interconnected 
porous network (<0.1 μm) allowing for diffusion of both gentamicin and Dhvar-5 from 
deeper layers of the bone cement. Ultimately, resulting in a more sustained and 
enhanced release of both gentamicin and Dhvar-5. The increase in burst release by 
consecutive higher admixture of Dhvar-5 (Chapter 3, Figure 1) can be explained in part 
by an increase in surface roughness as seen on the SEM micrographs. Whereas, the 
sustained higher release of gentamicin for 21 days from the OstG-25 and OstG-50 
cement (Chapter 3, Figure 2) can be explained by an increase in porosity (Figures 3B, D 
59
Mechanical and architectual properties of PMMA bone cements
and F). The prolongation of the initial gentamicin burst release in both the OstG-25 and 
OstG-50 bone cements is a step forward to the ideal release proﬁ le as described by van 
de Belt et al. (van de Belt et al., 1999). Although, the long term low level release was 
still present in the investigated cement mixtures.
 The admixture of both gentamicin and Dhvar-5 to PMMA could also have 
advantages from a microbiological point of view, as these two antimicrobial agents with 
two different mechanisms of action are less likely to induce resistance and could even 
act synergistically (van ‘t Hof et al., 2000). However, further research is necessary to 
investigate the combined antimicrobial activity of both gentamicin and Dhvar-5. The 
admixture of Dhvar-5 would need to have a proven microbiological advantage besides 
increasing the amount of gentamicin release, as the admixture of lactose would be a 
cheaper way of achieving this goal (Virto et al., 2003).
 As the admixture of antibiotics can adversely affect the mechanical properties 
of PMMA bone cement (Lautenschlager et al., 1976), we also investigated the 
compressive strength of the polymerised Ost-50 and Ost-100 PMMA bone cement. 
A progressive decrease in strength was observed, but the compressive strength of 
the Ost-50 and Ost-100 cement did meet the minimal requirements of the iso 5833 
standard. As expected, the compressive strength of the Osteopal was higher than that 
of Osteopal G (Figure 4). The admixture of 25 or 50 mg Dhvar-5/g of cement powder 
to the Osteopal G cement did not further reduce the compressive strength signiﬁ cantly. 
Adequate compressive strength is however not the only mechanical property a clinical 
bone cement must have before application as prosthesis ﬁ xation can be considered. 
Further research is necessary to determine all mechanical properties, e.g. tensile, 
bending and fatigue strengths of PMMA containing Dhvar-5. The results did show that 
the application of Dhvar-5 in a PMMA bone cement is not necessarily restricted to the 
use in non-weight-bearing applications, i.e. in the form of beads. 
 In conclusion, the high release of Dhvar-5 and gentamicin from PMMA bone 
cement is probably due to increased micro-porosity (<0.1 μm) which occurs due to 
the dispersion and subsequent dissolution of Dhvar-5 through the PMMA matrix. This 
research provides a basis for the further development and adjustment of PMMA bone 
cements containing different or several antimicrobial agents.
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In vivo comparison of Dhvar-5 and gentamicin in an
MRSA osteomyelitis prevention model
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In vivo comparison of Dhvar-5 and gentamicin in an MRSA 
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Abstract
The continued rise in drug-resistant pathogens has led to global research efforts 
into new antimicrobial agents. A promising class of new agents are the antimicrobial 
peptides. In this study we investigated the efﬁ cacy of the antimicrobial peptide Dhvar-
5 in a prophylactic, methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis 
model. Dhvar-5 (12 mg or 24 mg/rabbit) was incorporated into polymethyl methacrylate 
(PMMA) beads as a local drug delivery system. For comparison plain beads (control) 
and beads containing gentamicin (10 mg or 24 mg /rabbit) were also prepared. The 
beads were inserted into the inoculated femoral cavity of 36 rabbits, and one week 
later the animals were sacriﬁ ced. The presence and severity of MRSA osteomyelitis 
was assessed by culture and histology. Both the 24 mg Dhvar-5 beads and the 24 mg 
gentamicin sulphate beads signiﬁ cantly reduced the bacterial load of the inoculated 
femora compared to the control chain. Although a 24 mg Dhvar-5 dose inhibited MRSA 
growth, it did not completely sterilize the femora. Sterilization occurred only in some of 
the gentamicin-treated specimens. We conclude that both the gentamicin beads and the 
Dhvar-5 beads were only partially effective at preventing MRSA infection in this model. 
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Introduction
Osteomyelitis causes major morbidity and remains a difﬁ cult complication 
to treat in orthopedic surgery. Radical surgical debridement with local administration 
of antibiotics e.g. gentamicin-loaded polymethyl methylacrylate (PMMA) beads in 
combination with systemic antibiotics is the treatment of choice (Walenkamp et al., 
1998). Mixtures of the artiﬁ cial resin PMMA and antibiotics have also been used for 
several decades as bone cement with the ability to prevent and/or to treat orthopaedic 
infections in combination with systemic antibiotics (Buchholz et al., 1981; Josefsson et 
al., 1993).
Gentamicin incorporation into PMMA has long been the primary choice of 
physicians for the local treatment of osteomyelitis (Marks et al., 1976; Walenkamp et 
al., 1998). Gentamicin is a broad spectrum antibiotic, which is active against both Gram-
positive and Gram-negative bacteria (Hill et al., 1977). The exothermic polymerisation 
process of the PMMA does not inﬂ uence the bioactivity of gentamicin (Buchholz et al., 
1970; Wahlig et al., 1978). The long-term release proﬁ les of gentamicin from PMMA 
beads have been demonstrated in kinetic release studies (Wahlig et al., 1978). Overall, 
the use of gentamicin-loaded PMMA beads results in high local antibiotic bone and soft 
tissue concentrations versus low systemic concentrations, thus reducing side effects of 
gentamicin (Wahlig et al., 1978). On the contrary, a high systemic dosage of gentamicin 
needed to reach sufﬁ cient tissue penetration would create serious toxic side effects 
(Craig, 1995).
However, recent studies have shown an increase in antibiotic-resistant bacteria 
such as gentamicin-resistant S. aureus (GRSA) and MRSA (Witte, 1999). Prevalence of 
MRSA in nosocomial infections has exceeded 30% in many countries, e.g. southern 
Europe and the US (Kac et al., 2000; Witte, 1999). Neut et al. demonstrated growth of 
resistant staphylococci on retrieved gentamicin-loaded PMMA beads, raising concern 
about the efﬁ cacy of this treatment option (Neut et al., 2001). Furthermore, ﬁ rst reports 
of S. aureus vancomycin resistance are now published (Whitener et al., 2004). As current 
antibiotic therapy options for staphylococcal infections are becoming limited, there is 
an urgent need for new antimicrobial agents to combat these resistant pathogens.
Antimicrobial peptides (AMPs) are a new and promising class of antibiotics, 
derived from naturally occurring peptides (Hancock, 1997). These peptides are found 
on epithelial surfaces, in secretion ﬂ uids and in neutrophils, and thus form a ﬁ rst line 
of host defense as part of the innate immune system (Zasloff, 2002). AMPs have 
generated a lot of interest as possible new antimicrobial agents, van ’t Hof has reviewed 
several AMPs under investigation (van ‘t Hof et al., 2001). An advantage is that they 
have a diminished tendency to induce resistance because of the evolutionary difﬁ culty 
in changing bacterial membrane structure (Hancock, 1997; Zasloff, 2002).
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Dhvar-5 is an experimental AMP based on histatin-5, which is an antifungal 
peptide found in human saliva (Helmerhorst et al., 1999). Dhvar-5 has been designed 
to create a net positive charge at the C-terminus and a hydrophobic N-terminus 
(LLLFLLKKRKKRKY) (Helmerhorst et al., 1997). The positive charge is presumed to play a 
crucial part in its antimicrobial activity. It disrupts and penetrates the negatively charged 
bacterial cell wall; and after cellular entrance it is targeted to intracellular organelles 
(Helmerhorst et al., 1999). The Dhvar-5 peptide has fungicidal and bactericidal activity 
as well as antimicrobial activity against MRSA in vitro (Lyaruu et al., 2000; Ruissen et 
al., 2001).
In the light of antimicrobial resistance and the urgent need for new antimicrobial 
agents, we previously investigated the suitability of PMMA mini-beads as a carrier of 
Dhvar-5 (Faber et al., 2003). These beads showed a high and prolonged in vitro release 
of Dhvar-5 in its biologically active form (Faber et al., 2003). Therefore, the aim of the 
present investigation was to evaluate the efﬁ cacy of Dhvar-5 and gentamicin beads in 
an in vivo MRSA osteomyelitis prevention model.
Materials and Methods
Experimental Design
The femoral cavity of 36 rabbits was inoculated with approximately 107 colony-
forming units (cfu) of MRSA in a modiﬁ ed prophylactic osteomyelitis model described by 
Nijhof et al. (Nijhof et al., 2000). Immediately after inoculation, a custom-made PMMA 
mini-bead chain was inserted into the femur. The chains were prepared as described 
earlier (Faber et al., 2003), the control group (n=7) received a chain of 10 plain cement 
beads (Osteopal®, Biomet Merck, Darmstadt, Germany) without antibiotic. The AMP-
treated animals received a chain of 10 beads containing a total of 12 mg (n=7) or 24 mg 
(n=9) Dhvar-5. The gentamicin-treated animals received a chain prepared from Osteopal 
G® (Biomet Merck, Darmstadt, Germany) containing a total of either 10 mg (n=7) or 24 
mg (n=5) gentamicin sulphate. After seven days, the animals were sacriﬁ ced and the 
femoral cortex was cultured for the presence of MRSA and the number of cfu per gram 
bone tissue were determined as a measure for treatment outcome. 
Animals 
Female New Zealand White (NZW) rabbits (3.5-4 kg) were obtained 3 weeks 
prior to surgery and allowed to acclimatize to the Clinical Animal Laboratory, Vrije 
Universiteit Medical Center (VUmc). The animals were housed in groups and allowed 
water and antibiotic-free rabbit diet ad libitum. The experimental protocol was approved 
by the Animal Ethics Committee of our institution.
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Preparation of PMMA mini-beads  
The bead chains were prepared as described earlier (Faber et al., 2003). In 
short, two different quantities of Dhvar-5 (50 mg and 100 mg/gram of cement powder) 
were mixed with the cement powder. The liquid monomer was added in a 1:2 liquid to 
powder ratio and the resulting cement paste was injected into a custom-made mould. 
The cement was allowed to polymerize on a stainless steel wire (0.3 mm ∅), removed 
from the mould and stored at −20°C until use. This process produced a chain of 10 
beads containing a total of either 12 mg or 24 mg of Dhvar-5. The 10 mg gentamicin 
sulphate chains were obtained by injecting the commercially available Osteopal G® 
(Biomet Merck, Darmstadt, Germany) bone cement into the mould. The gentamicin 
content of the Osteopal G® powder was augmented from 41.75 mg to 100 mg 
gentamicin sulphate/g cement powder (= 60 mg gentamicin/g) to produce the 24 mg 
gentamicin sulphate chain. From here on, the group dosages referred to as gentamicin 
are the gentamicin sulphate dosages. As each animal received one chain of 10 beads 
during surgery, the dosages mentioned are the amount of antibiotics incorporated into 
a chain of 10 beads, and therefore the amount per animal.
Bacterial strain
The MRSA strain (ATCC: BAA-811) was isolated form an osteomyelitis patient 
and was resistant to several antibiotics including gentamicin (Table 1). An overnight 
culture was grown in brain heart infusion (BHI) broth and washed in PBS. Subsequently, 
aliquots were prepared and stored at -80°C. The amount of viable cfu was determined 
in defrosted aliquots by serial dilution and plating on blood agar. At the day of surgery 
a fresh aliquot was allowed to thaw and a bacterial suspension of 108 cfu/ml was 
prepared in PBS. The femoral canal was inoculated by a direct injection of 0.1 ml 
bacterial suspension (107 cfu). After surgery the inoculum was serially diluted and plated 
on blood agar for control of viable cfu count. 
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Table 1;  Minimal inhibitory concentrations (MIC) of the MRSA strain (ATCC: 
 BAA-811) used in this study. Values were determined by the broth 
 dilution method in BHI for Dhvar-5 and the disc diffusion method for 
 the other antibiotics.(Lorain, 1996)
Staphylococcus aureus
(ATCC: BAA-811)
Antibiotic MIC (mg/L)
Dhvar-5 12.5 mg/L
Oxacilin > 256 mg/L
Penicillin > 32 mg/L
Vancomycin 1.5 mg/L
Clindamycin 256 mg/L
Erythromycin > 256 mg/L
Gentamicin 256 mg/L
Anesthesia and surgery
The animals were weighed and sub-cutaneously (sc) injected with xylazine 2.5 
mg/kg (Xylalin, CEVA Sante Animale, Maassluis, The Netherlands) and ketamine 62.5 
mg/kg (Aescoket, Aesculaap, Boxtel, The Netherlands). Once sedated, the right hip 
area was shaved and painted with iodine. Subsequently, lidocaine 5 mg/kg (Pharmacy 
VUmc, Amsterdam, the Netherlands) was injected around the greater trochanter. Pre-
operative blood samples were taken from the right auricular vein for the determination 
of peripheral white blood cell count (WBC) and erythrocyte sedimentation rate (ESR). 
The animals were placed on their left side and the skin was again painted with iodine 
and the surgical area was isolated with sterile drapes. During surgery, the anesthesia 
was maintained by free ﬂ ow inhalation of a gas mixture containing 45% oxygen; 53.5% 
air and 1.5% isoﬂ urane (Forene, Abbot BV, Hoofddorp, the Netherlands). 
A 3 cm skin incision was made parallel to the femur shaft over the trochanter 
major of the right femur. After splitting the fascia and retracting the femoral biceps, the 
trochanter was exposed and the bone was notched to mark the drill site. The cortex 
was penetrated with a small drill (2.0 mm diameter), which was gradually increased to 
3.5 mm diameter. The femoral canal was reamed with small stainless-steel brushes 
(Abrasives Center, Maastricht, The Netherlands) increasing in size up to 4.0 mm 
diameter. Subsequently the canal was ﬂ ushed with 50 ml 0.9% NaCl solution to remove 
any bony debris created by the reaming procedure. In quick succession, the bacterial 
inoculation (0.1 ml) was injected and the beads inserted (Figure 1). The fascia and skin 
were closed with Vicryl 4/0. Post-operative pain relief was provided by injection of 0.15 
mg buprenorphine (sc), which was repeated if necessary. 
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Figure 1  Radiograph of a dissected femur showing the PMMA bead chain in 
 situ (arrow) and the drill hole (arrowheads) 3.5 mm in diameter. No 
 radiological signs of osteomyelitis are present after 1 week of 
 follow-up. 
Autopsy and sample acquisition
After 7 days, the animals were euthanatized, ﬁ rst by sedation with an 
injection (sc) of 2.5 mg/kg xylazine and 62.5 mg/kg ketamine, and then killed by 
an intravenous injection of 75 mg/kg pentobarbital (Nembutal, CEVA Sante Animale, 
Naaldwijk, The Netherlands). Blood samples were drawn for white blood cell count 
(WBC) and erythrocyte sedimentation rate (ESR) determination before administration of 
the pentobarbital. The right and left (control) femur were excised under strict aseptic 
conditions. After excision, radiographs of all femora were taken to document possible 
signs of osteomyelitis. Then, a transverse saw cut was made in the middle of the femur, 
care being taken not to damage the bead chain inside the femoral canal. The bead chain 
was then gently removed from the femoral cavity. Subsequently, transverse sections 
were sawn from all proximal femora, for histological and bacteriological analysis.
Bacterial cultures
A transverse section of approximately 1 gram from the proximal half of the 
femur was weighed and then homogenized in 50 ml of PBS at 15,000 rpm for 2 minutes 
(Sorval Omnimix, Dupont Instruments, Newton, Connecticut, USA). A serial dilution was 
plated on blood agar and incubated for 24 h at 37 °C. The bacterial load was expressed 
as cfu per gram of bone tissue. The detection limit of this method was approximately 
2.5 x 103 cfu/g bone depending on the mass of the speciﬁ c homogenized bone section. 
For statistical analysis, the sterile and/or negative samples of the quantitative assay 
were considered to have the detection limit value (≈ 2.5 x 103 cfu/g bone) of bacterial 
load. Additionally, in order to asses the possible presence of MRSA below the detection 
limit of the quantitative method, a 100 μl sample of bone homogenate was cultured in 
brain heart infusion (BHI) broth for at least 48 hrs at 37 °C. 
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Histology
Bone samples were ﬁ xed in 4% formaldehyde in 0.1 M phosphate buffer 
(pH 7.2) and stored for at least 24 hrs at + 4 °C, then thoroughly washed in PBS, 
dehydrated in ascending alcohol series and then embedded in polymethyl methacrylate 
without plastoid (Theuns et al., 1993). Undercalciﬁ ed 30 μm thick sections were made 
with a 300 μm thick diamond-edge saw blade (Klein et al., 1994), and stained with a 
mixture of fuchsin and methylene blue.
Disease severity was assessed by a modiﬁ ed Smeltzer score (Smeltzer et 
al., 1997). Disease severity is scored on the basis of periosteal inﬂ ammation, acute 
intra-medullar inﬂ ammation, chronic intra-medullar inﬂ ammation, and bone necrosis. 
However, as the complete histopathology normally takes more than 7 days to manifest 
itself; only early signs of infection were scored, in particular, the presence of a periosteal 
reaction and necrotic bone.
Statistical analysis
The results of bacterial cultures were analyzed using the Statistical Package 
for the Social Sciences (SPSS) version 10.1 for windows. The student’s t-test for 
independent samples was used to analyze the quantitative microbiological data. The 
paired t-test was used for the analysis of body weight, temperature, WBC count and 
ESR changes. And for analysis of these parameters between groups the one way 
analysis of variance (ANOVA) was used. Furthermore, one-sided tests were performed 
for comparison of each antibiotic group to the sham treated control group, and two-
sided tests were performed for the comparison of Dhvar-5 and gentamicin groups. 
Differences were considered signiﬁ cant at p < 0.05.
Results
General
All animals tolerated and recovered well from surgery. However, two animals 
from the 12 mg Dhvar-5 and one from the 24 mg Dhvar-5 group sustained a per-
operative trochanter fracture and were thus excluded from the study. Also, one control 
rabbit was excluded due to a superﬁ cial infection. In total 32 rabbits were included for 
statistical analysis. 
There were no signiﬁ cant differences in weight or in temperature between 
the different groups (Figures 2A and 2B). Within groups, the 12 mg Dhvar-5 group lost 
3.8% of its body weight (p = 0.005), and the control group showed a minor increase in 
temperature of 0.5°C (p=0.05), no other signiﬁ cant differences were found.
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Also, there were no differences in the WBC values between groups pre-
operatively and at day 7 (Figure 2C). Within groups, the WBC increased signiﬁ cantly 
from pre-operative to day 7 values in both the control (p = 0.05) and the 12 mg Dhvar-5 
group (p = 0.01). There were no differences in ESR between groups except for the 12 
mg Dhvar-5 group (Figure 2D), which had a signiﬁ cant increase and was higher compared 
to the other groups (p=0.04). As expected, after 7 days follow-up, the radiographs did 
not show signs of infection (Figure 1). 
 
 
Figure 2 A – D: Body weight (A) and temperature (B) were measured pre-
 operatively (white bars) and at 7 days follow-up (black bars) 
 (values are mean ± SD). The 12 mg Dhvar-5 group suffered 
 mild weight loss (ap = 0.005) and the control group had a 
 slight increase in temperature (bp = 0.05). There were no 
 other signiﬁ cant differences between the groups in weight 
 and temperature. The WBC (C) increased signiﬁ cantly in the 
 controls (cp = 0.05) and 12 mg Dhvar-5 group (dp = 0.01). 
 Furthermore, the ESR (D) increased signiﬁ cantly from the pre-
 operative to the day-7 value in the 12 mg Dhvar-5 group and 
 was signiﬁ cantly higher compared to the other groups (ep = 
 0.04). No pre-operative differences were seen between 
 groups.
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Microbiology
Quantitative data of the cultures from the femora are shown in Figure 3. In the 
sham-treated control group a mean (±SD) of 1.9×106 (±2.0×106) cfu/g bone (n=7) were 
cultured and in the 12 mg (n=7) and 24 mg (n=7) Dhvar-5 group, 0.78x106 (±0.4×106) 
and 0.51×106 (±0.3×106) cfu/g bone, respectively. The difference between the control 
and the 24 mg Dhvar-5 group was signiﬁ cant (p=0.04); between the 12 mg Dhvar-5 and 
control group this difference almost reached signiﬁ cance (p=0.07). Furthermore, in the 
10 mg and 24 mg gentamicin group a mean of 0.55×106 (±1.1×106) cfu/g bone and 
0.09×106 (±0.2×106) cfu/g bone were cultured, respectively. The difference between 
control and the 10 mg gentamicin group almost reached signiﬁ cance (p=0.06), while 
the 24 mg gentamicin group had a signiﬁ cantly lower colony count compared to the 
controls (p=0.02) and compared to 24 mg Dhvar-5 (p=0.04). All left femora (not 
operated control) were sterile and did not show any growth of bacteria.
Bacteria were retrieved from all control animals and from all Dhvar-5-treated 
animals (Table 2). Successful prevention of osteomyelitis indicated by sterile BHI cultures 
after 48 hrs was achieved in 3/7 and 3/5 animals of the 10 mg and 24 mg gentamicin 
group, respectively.
Table 2;  Qualitative microbiological data is shown as the number of animals 
 per group from which bacteria were cultured in the BHI after 48hrs 
 at 37°C. Furthermore, the number of animals with early 
 histopathological signs of osteomyelitis are described per group.
Histology (/N)
Bead chain MRSA (/N) Periosteal reaction Bone necrosis
Control 7 / 7 7 / 7 6 / 7
12 mg Dhvar-5 6 / 6 6 / 6 6 / 6
24 mg Dhvar-5 7 / 7 6 / 7 6 / 7
10 mg Gentamicin 4 / 7 5 / 7 7 / 7
24 mg Gentamicin 2 / 5 3 / 5 3 / 5
Histology
Table 2 presents the histopathological results. In control animals minor 
periosteal reaction (Figures 4A and 4B) was seen in all animals (7/7) and femoral 
necrosis in 6/7 animals. Similar results were seen in the 12 mg and 24 mg Dhvar-
5 group with a minor periosteal reaction in 6/6 and 6/7 animals respectively. Bone 
necrosis was found in all but one of the 24 mg Dhvar-5 treated group. One animal 
of the 24 mg Dhvar-5 group had no signs of osteomyelitis. In the 10 mg gentamicin 
group 5/7 animals showed a periosteal reaction and 7/7 showed bone necrosis. In 
the 24 mg gentamicin group 3/5 animals showed early signs of osteomyelitis. The 
histopathological scores revealed no signiﬁ cant differences between the groups (data 
not shown).
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Figure 3;  Quantitative microbiological analysis at day 7, plotted are average 
 counts of cfu per gram of bone tissue (+ SE). The 24 mg Dhvar-5 and 
 24 mg gentamicin group signiﬁ cantly reduced the bacterial load 
 compared to control (ap = 0.04, bp = 0.02). Also, the 24 mg 
 gentamicin group reduced the cfu count more than the 24 mg 
 Dhvar-5 group (cp = 0.04). Both the 12 mg Dhvar-5 and the 10 mg 
 gentamicin groups showed a trend towards reducing the bacterial 
 load, p = 0.07 and p = 0.06 respectively.
Discussion
In this study we used a prophylactic model which was modiﬁ ed from the 
model described by Nijhof et al. (Nijhof et al., 2000). Instead of self-setting PMMA bone 
cement we used custom-made PMMA beads of the same dimensions (3×5 mm) as 
the commercially available Septopal® mini-beads (Biomet Merck, Darmstadt, Germany). 
These mini-beads were then inserted into the inoculated femoral canal (Figure 1). The 
MRSA strain was a clinical isolate from a patient with osteomyelitis and was therefore 
considered to be sufﬁ ciently virulent to generate osteomyelitis in vivo consistently. 
To further ensure a reproducible infection model with 100% infection in sham-treated 
control animals, the number of cfu injected was increased to 107 cfu, as opposed to the 
106 cfu described by Nijhof et al. (Nijhof et al., 2000). These measures resulted in 100% 
infection rate in the sham treated control group (Norden et al., 1980).
*
a
*
b,c
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The main advantages of this model are the minor systemic signs of infection 
observed (Figures 2A and 2B). Despite the relatively large inoculum (107 cfu), none 
of the operated animals developed sepsis. This was also reﬂ ected in the systemic 
infection parameters, which showed only minor changes in all groups (Figures 2C and 
2D). Another advantage of this study model is the good and reproducible distribution 
of PMMA beads throughout the femoral canal (Figure 1), the number and proximity of 
antibiotic beads is well known to inﬂ uence antibiotic tissue levels in the bone (Wahlig 
et al., 1978). Local treatment of osteomyelitis consists of debriding necrotic bone and 
inserting as much as possible antibiotic beads into the medullary canal, adding to the 
clinical relevance of this model (Walenkamp et al., 1998).
The data presented show that 24 mg Dhvar-5 incorporated in custom made 
PMMA mini-beads can inhibit MRSA proliferation in vivo, signiﬁ cantly reducing bacterial 
load compared to controls (p = 0.04) (Figure 3). The 12 mg group also demonstrated 
a trend (p = 0.07) towards reduction of bacterial load per gram of bone. The data 
therefore suggest a dose response effect of Dhvar-5 in vivo (Figure 3). Nevertheless, 
even a high dose Dhvar-5 was not able to eradicate all bacteria and sterilize the femur. 
The 24 mg gentamicin group on the other hand showed inhibition of MRSA proliferation 
(p = 0.02) and sterilized 3 out of 5 femora (Table 2 and Figure 3). The low dose 
gentamicin (10 mg) group showed a trend (p = 0.06) towards reducing the number of 
cfu per gram of bone and sterilized 3 out of 7 femora. All animals treated with control 
beads developed an infection (Table 2).
Figure 4 A – D: Figure 4A Survey micrograph of a transverse section from a 
 control femur (fuchsin and methylen blue, magniﬁ cation 
 25x). The arrowheads indicate remnants of the blood clot 
 which still imbeds the beads are after 7 days. An early 
 periosteal reaction can be seen (arrows). Figure 4B is a 
 detail of the periosteal reaction (magniﬁ cation 200x), this 
 phenomenon was also seen in other groups (see Table 2). 
 Figure 3C is a high magniﬁ cation (200x) of a control femur, 
 necrotic bone can be identiﬁ ed by empty lacunae 
 (arrowheads). Figure 3D shows a gentamicin treated femur 
 without periosteal reaction (magniﬁ cation 200x), this animal 
 was also found to be sterile.
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Figure 4 A – D:
The MRSA strain was highly resistant to several antibiotics including gentamicin 
(MIC = 256 μg/ml, Table 1). Despite this marked resistance, the high dose gentamicin 
beads did prevent infection in 3 of 5 the rabbits. Several studies have shown that the 
local application of gentamicin in PMMA beads can result in local bone tissue levels 
around this high MIC value (Harle et al., 1979; Wahlig et al., 1978), thus explaining the 
ability of the gentamicin beads to sterilize some of the femurs in this study.
B DC
ACortex
Cortex
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There are numerous reports indicating an increase in antimicrobial resistance, 
in particular of S. aureus and coagulase negative staphylococci (CNS) (Denis et al., 
2002; Hornberg et al., 2001; Hornberg et al., 2003; Kac et al., 2000; Witte, 1999). 
Besides the high prevalence of MRSA, also ﬁ rst strains of vancomycin-resistant S. aureus 
(VRSA) have now been reported (Whitener et al., 2004). Moreover, the development of 
antimicrobial resistance is increased in bioﬁ lms (Stewart et al., 2001). The formation of 
bioﬁ lms renders bacteria very resistant to conventional antibiotics and can even result 
in bacteria colonizing gentamicin-containing PMMA beads (Neut et al., 2001). These 
developments have increased concern over the future applicability of conventional 
antibiotics, and spurred the development of novel antimicrobial agents (Giacometti et 
al., 2002; Giacometti et al., 2003; Giacometti et al., 2004; Groenink et al., 1999; 
Hancock, 1997; Levin et al., 2000; Navon-Venezia et al., 2002; Nibbering et al., 2001; 
Steinstraesser et al., 2002; Zasloff, 2002).
Over the past decade numerous naturally occurring AMPs have been 
identiﬁ ed and their pivotal role in the mechanism of our innate immune system has been 
discovered (Hancock, 1997; Zasloff, 2002). Several research groups have speciﬁ cally 
described options for the development of AMPs as new antimicrobial agents (Giacometti 
et al., 2002; Giacometti et al., 2003; Giacometti et al., 2004; Groenink et al., 1999; 
Hancock, 1997; Levin et al., 2000; Navon-Venezia et al., 2002; Nibbering et al., 2001; 
Steinstraesser et al., 2002; Zasloff, 2002). The rBPI21 antimicrobial peptide has reached 
phase III clinical trials and has shown promising clinical results: improving the outcome 
of meningococcal sepsis in children (Levin et al., 2000). Van ‘t Hof et al. has reviewed a 
large number of AMPs currently under investigation (van ‘t Hof et al., 2001).
Based on our in vitro release study, we ﬁ rst chose to incorporate 12 mg 
and 24 mg Dhvar-5 in the PMMA beads (Faber et al., 2003), as this should have 
resulted in a continuous release of sufﬁ cient quantity of Dhvar-5 to kill bacteria at the 
inoculated site for the duration of the experiment. The high dose of Dhvar-5 resulted in 
a signiﬁ cantly reduced bacterial load per gram of bone (Figure 3). However, as there 
was no method available to measure in vivo concentrations of Dhvar-5, we could not 
determine the systemic or local concentrations of Dhvar-5. It is therefore difﬁ cult to 
relate the very high release characteristics of Dhvar-5 in vitro to the results obtained in 
vivo. There is no data available on the in vivo half-life of Dhvar-5. Other AMPs are known 
to have a much shorter half-life than gentamicin (Nibbering et al., 2001). It is therefore 
possible that Dhvar-5 is cleared more rapidly then gentamicin. Also, in vitro studies have 
shown that Dhvar-5 can be degraded by protoeolytic enzymes such as trypsin (Den 
Hertog et al., 2004). This could possibly reduce local tissue levels of Dhvar-5 in vivo. 
Furthermore, some AMPs have been reported to bind to serum proteins, resulting in 
reduced antimicrobial activity (Wang et al., 2004). In this study a combination of these 
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factors could have resulted in lower local free and/or active tissue concentrations of 
Dhvar-5, possibly compromising the in vivo efﬁ cacy. Thus explaining the relatively better 
performance of the gentamicin beads compared to the Dhvar-5 beads in this study, 
despite the marked gentamicin resistance of the MRSA strain.
This study demonstrates the in vivo antimicrobial activity of Dhvar-5 against 
MRSA. Future development of Dhvar-5 and other AMPs as a novel antimicrobial 
agents is largely dependent on the ability to control aspects as the pharmaco-
dynamics, inhibition of enzymatic proteolysis and prevention of possible inactivation 
by binding to proteins. Numerous opportunities can be found in changing amino 
acid sequences whilst retaining or even improving the antimicrobial activity. This 
research provides a basis for the further development of AMPs as an alternative 
for conventional antibiotic agents for the treatment of drug resistant pathogens.
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Abstract
The therapeutic efﬁ cacy of the antimicrobial peptide, human lactoferrin (1-11) 
(hLF1-11) was investigated in a chronic MRSA (gentamicin-susceptible) osteomyelitis 
model in rabbits. 50 mg hLF1-11 or 50 mg gentamicin per gram cement powder 
were incorporated into a calcium phosphate bone cement (Ca-P) and injected into the 
debrided tibial cavity, creating a local drug delivery system. The efﬁ cacy of hLF1-11 and 
gentamicin was compared to that of a sham-treated control (plain bone cement) and 
no treatment (infected only). The results were evaluated by microbiology, radiology and 
histology. MRSA was recovered from all tibia’s in both control groups (n=11). On the 
other hand hLF1-11 and gentamicin signiﬁ cantly reduced the bacterial load. Furthermore, 
no growth of bacteria was detected in 5 out of 8 and 6 out of 8 specimens of the 
hLF1-11- and gentamicin-treated groups respectively. These results were conﬁ rmed 
by a signiﬁ cant reduction of the histological disease severity score by hLF1-11 and 
gentamicin compared to both control groups. The hLF1-11 treated group also had a 
signiﬁ cantly lower radiological score compared to the gentamicin-treated group. This 
study demonstrates the efﬁ cacy of hLF1-11 incorporated into calcium phosphate bone 
cement as a possible therapeutic strategy for the treatment of osteomyelitis, showing 
comparable efﬁ cacy to that of gentamicin. Therefore, the results of this study warrant 
further pre-clinical investigations into the possibilities of using hLF1-11 for the treatment 
of osteomyelitis.
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Introduction
Osteomyelitis causes major morbidity and remains the most feared and 
difﬁ cult infection to treat in orthopedic surgery. Radical surgical debridement with local 
administration of antibiotics e.g. gentamicin-loaded polymethyl methylacrylate (PMMA) 
beads in combination with systemic antibiotics has been the treatment of choice (Jenny, 
1988; Walenkamp et al., 1998; Walenkamp, 2001). The major disadvantage of PMMA-
beads is the necessity to remove them after they have eluded their antibiotics, requiring 
an additional surgical procedure (Jenny, 1988; Walenkamp et al., 1998; Walenkamp, 
2001). Numerous investigations have been performed to develop other resorbable / 
biodegradable carriers for several antibiotics (Castro et al., 2003; Kanellakopoulou et 
al., 2000).
Gentamicin has long been the primary choice of orthopaedic surgeons for 
local treatment of osteomyelitis (Marks et al., 1976; Walenkamp et al., 1998). This 
aminoglycoside is a broad spectrum antimicrobial agent, which is active against both 
Gram-positive and Gram-negative bacteria (Hill et al., 1977). The long-term release 
proﬁ les of gentamicin from PMMA and calcium phosphate bone cements have been 
demonstrated in kinetic release studies (Kanellakopoulou et al., 2000; Wahlig et al., 
1978). Overall, the use of gentamicin-loaded PMMA beads results in high local antibiotic 
bone and soft tissue concentrations versus low systemic concentrations, thus reducing 
systemic side effects (Wahlig et al., 1978). On the contrary, a high systemic dosage 
of gentamicin needed to reach sufﬁ cient tissue penetration would create serious toxic 
side effects (Craig, 1995).
Over the past years, studies have shown an increase in antibiotic-resistant 
bacteria such as gentamicin-resistant S. aureus (GRSA) and MRSA (Witte, 1999). 
Prevalence of MRSA in nosocomial infections has exceeded 30% in some countries, 
e.g. southern Europe and the US (Kac et al., 2000; Witte, 1999). Several authors 
have also demonstrated the presence of gentamicin-resistant staphylococci after 
gentamicin-loaded PMMA bead therapy, raising concern about the efﬁ cacy of this 
treatment option (Neut et al., 2001; von Eiff et al., 1997). Furthermore, reports on 
staphylococcal infections with reduced susceptibility or resistance to vancomycin are 
emerging (Whitener et al., 2004). As current antibiotic therapy options are becoming 
limited for staphylococcal infections, there is an urgent need for new antimicrobial 
agents to combat these resistant pathogens.
Antimicrobial peptides (AMPs) are a new and promising class of antimicrobial 
agents derived from naturally occurring peptides (Hancock, 1997). These peptides are 
found on epithelial surfaces, in secretion ﬂ uids and in neutrophils, and thus form a ﬁ rst 
line of host defense as part of the innate immune system (Zasloff, 2002). Furthermore, 
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they are thought to have a diminished tendency to induce resistance because of the 
evolutionary difﬁ culty in changing bacterial membrane structure (Hancock, 1997; 
Zasloff, 2002). These properties together with the antimicrobial activity against a broad 
variety of pathogens have made AMPs attractive candidates for antimicrobial drug 
development (van ‘t Hof et al., 2001).
The antimicrobial peptide human lactoferrin 1-11 (hLF1-11) is derived from 
the active domain of human lactoferrin (N-terminal amino acids 1-11) (Lupetti et al., 
2000). hLF1-11 has a broad antimicrobial spectrum in vitro against both bacteria and 
fungi (Lupetti et al., 2000; Lupetti et al., 2003; Nibbering et al., 2001). Furthermore, 
Nibbering et al. demonstrated the efﬁ cacy of hLF1-11 in vivo, reducing the number 
of bacteria (MRSA) after systemic administration in the mouse thigh infection model 
(Nibbering et al., 2001). 
In the light of antimicrobial resistance and the urgent need for new antimicrobial 
agents, we previously investigated the efﬁ cacy of using calcium phosphate bone cement 
as a carrier for hLF1-11 (Stallmann et al., 2003). In general, calcium phosphate bone 
cements showed a high and prolonged in vitro release of hLF1-11 in its biologically active 
form (Stallmann et al., 2003). Furthermore, we also showed that hLF1-11 incorporated 
into calcium phosphate bone cement can prevent S. aureus osteomyelitis in rabbits 
(Stallmann et al., 2004). Therefore, the aim of the present investigation was to evaluate 
and compare the performance of hLF1-11 and gentamicin incorporated into calcium 
phosphate bone cement to treat a pre-existing MRSA osteomyelitis in rabbits.
Materials and Methods
Experimental Design
The study was set-up according to the well described osteomyelitis model of 
Norden et al. (Norden et al., 1980). The proximal right tibia of 27 New Zealand White 
rabbits were inoculated with approximately 3 x 106 colony forming units (cfu) MRSA. 
After three weeks (day 21), treatment was initiated, except for ﬁ ve control animals 
which were sacriﬁ ced at this time point. Six animals were assigned to the sham-treated 
control group (n=6), receiving a thorough debridement and plain calcium phosphate 
bone cement (Calcibon®, Biomet Merck, Darmstadt, Germany). The remaining 16 
animals were also thoroughly debrided and received either 50 mg hLF1-11 (n=8) or 
50 mg gentamicin sulphate (n=8) per gram of bone cement powder (approximately 
20 mg/kg body weight). On day 42, 3 weeks after treatment, all treated animals were 
sacriﬁ ced and treatment outcome assessed by radiology, microbiology and histology. 
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Animals 
Female New Zealand White (NZW) rabbits (3.5-4kg) were obtained 3 weeks prior 
to surgery and allowed to acclimatize to the Clinical Animal Laboratory, VU University 
Medical Center (VUmc). The animals were housed in groups of 10 animals and were 
allowed water and antibiotic-free rabbit diet ad libitum. The experimental protocol was 
approved by the Animal Ethics Committee of the VU University Medical Center (VUmc).
Bacterial strain
The strain which was used for this study was a methicillin-resistant 
Staphylococcus aureus (MRSA) strain (strain W234) isolated from a patient with chronic 
osteomyelitis. Besides the resistance to all β-lactam antibiotics, the strain was also 
resistant to erythromycin, tetracycline, trimetroprim-sulfamethoxazole, and quinolones, 
but was susceptible to clindamycin, rifampin, aminoglycosides and glycopeptides (not 
shown). 
An overnight culture was grown in brain heart infusion (BHI) broth and washed 
in phosphate buffered saline (PBS). Subsequently, aliquots were prepared and stored 
at −80 °C. The numbers of viable colony forming units (cfu) were determined in the 
defrosted aliquots by serial dilution and plating on blood agar. At the day of surgery a 
fresh aliquot was defrosted and a bacterial suspension of approximately 3x107 cfu/ml 
was prepared in PBS. The tibial canal was inoculated by injection of 0.1 ml bacterial 
suspension (3x106 cfu). After surgery, the inoculates were serially diluted, plated on 
blood agar and cultured to conﬁ rm the number of viable bacteria. 
Surgery
The anesthesia was exactly the same for both the inoculation and the treatment 
of infection. After weighing, the animals were given a sub-cutaneous (sc) injection of 
xylazine 2.5 mg/kg (Xylalin, CEVA Sante Animale, Maassluis, The Netherlands) and 
ketamine 62.5 mg/kg (Aescoket, Aesculaap, Boxtel, The Netherlands) between the 
shoulder blades. Once sedated, the right knee area was shaven and washed with 
iodine solution. Subsequently, lidocaine 5 mg/kg (Pharmacy VUmc, Amsterdam, The 
Netherlands) was injected around the tuberculum and tibial plateau of the right tibia. 
Pre-operative blood samples were drawn from the auricular vein for the determination 
of white blood cell count (WBC) and erythrocyte sedimentation rate (ESR). The animals 
were then placed on their back, the skin painted again with iodine and the surgical area 
isolated with sterile drapes. During surgery, the anesthesia was maintained by free-ﬂ ow 
inhalation of a gas mixture containing 45% oxygen; 53.5% air and 1.5% isoﬂ urane 
(Forene, Abbot BV, Hoofddorp, The Netherlands). Post-operative pain relief was provided 
by sc injection of 0.15 mg buprenorphine, which was repeated if necessary.
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Inoculation of the tibia
A small stab incision was made over the tuberculum of the right tibia, 
subsequently 1.8 mm drill hole was made with a K-wire mounted on a hand-held drill. 
Then a 16G needle was inserted into the tibial cavity. Subsequently, 100 μl 5% sodium 
morrhuate (Scleromate™, Glenwood, Englewood, New Jersey, US) was injected, 
followed by the MRSA inoculum (3x106 cfu in 100 μl) through the same needle. The 
needle was then ﬂ ushed with 100 μl of 0.9% NaCl to ensure all bacteria reached the 
tibial cavity. The skin was subsequently closed with Vicryl 4/0.
Debridement and bone cement injection
The tibias were debrided 21 days after the ﬁ rst operation. A 3 cm incision was 
made over the pattello-tibial tendon, parallel to the tibial shaft. Subsequently, access to 
the tibal cavity was gained through the pattello-tibial tendon with a small drill (2.0 mm 
diameter), which was gradually increased to 3.5 mm diameter. The tibial canal was then 
debrided by reaming with stainless steel brushes (Abrasives Center, Maastricht, The 
Netherlands) increasing in size up to 4.0 mm diameter. It was attempted to remove 
as much infected and necrotic tissue as possible. Tissue remnants were whipped from 
the drills and brushes with conventional swabs and sent for culture. The canal was then 
ﬂ ushed with 100 ml 0.9% saline solution to remove any loose debris and remaining 
bone marrow. A suction cuvette was placed in the tibial canal until the cement was 
injected.
The calcium phosphate bone cement (2.5 g) (Calcibon®, Biomet Merck, 
Darmstadt, Germany) was prepared under strict sterile conditions on the surgical table 
according to the manufacture’s instructions. The cement paste was injected into the 
tibial cavity through a stainless steel cannule with an inside diameter of 2.4 mm, while 
slowly retracting the syringe. The syringe was weighed before and after injection to 
determine the amount of injected cement. Hereafter, the fascia and skin were closed 
with Vicryl 4/0. Pre- and post-operative X-rays were also taken to conﬁ rm the position 
of the bone cement and for the initial assessment of radiological osteomyelitis signs 
(Figure 1). 
Follow-up
All animals were monitored daily and examined at preset time-points; day 
1 (OP1), 2, 4 , 7 and thereafter every 7 days. After the second surgical procedure 
on day 21 the animals were examined more frequently, i.e., day 22, 24 and 28 and 
subsequently every 7 days until autopsy on day 42. During the examinations, the wound 
was inspected for signs of infection, the animals weighed and blood drawn from the 
auricular vein for WBC and ESR determination.
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Figure 1 A – B:  Pre-operative lateral radiograph (A) of the right tibia from a 
 sham-treated rabbit. Periosteal reaction is present 
 (arrowheads), and the drill hole can still be seen as a slight 
 shadow (arrow). The post-operative lateral radiograph (B) of 
 the same rabbit shows the cement in situ (arrows).
Autopsy and sample acquisition
On day 42, the animals were euthanized, ﬁ rst by sedation with a sc injection 
of 2.5 mg/kg xylazine and 62.5 mg/kg ketamine, and then sacriﬁ ced by an intravenous 
injection of 75 mg/kg pentobarbital (Nembutal, Ceva Sante Animale BV, Naaldwijk, 
Netherlands). The right tibias were excised under strict aseptic conditions. After 
excision, radiographs were taken to assess radiological disease severity.
A high speed dental drill was used to saw a standardized square bone sample 
(± 1 g) from the proximal medial tibia for quantitative microbiological analyses. The 
saw was cooled with physiological saline, and care was also taken not to damage the 
bone cement. Subsequently, the saw cut surfaces and interior of the bone sample were 
cultured with conventional swabs. A transverse section adjacent to the removed bone 
sample was processed for histological analyses. A strictly standardized protocol was 
enforced to insure that comparable samples were acquired. The samples for quantative 
microbiological analysis were then further processed by a technician blinded to the 
assigned groups.
Radiology
The radiographs obtained at the second procedure and at autopsy were 
randomized, scored by an independent orthopaedic surgeon. The standard osteomyelitis 
disease severity score of Norden et al. was used; this score is based on the presence of 
sequestra, periosteal new bone formation and destruction of bone (Norden et al., 1980). 
A B
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Involvement of the proximal, mid and distal tibia was also scored resulting in a maximum 
score of seven points. Animals were considered to have radiological osteomyelitis when 
the severity score was 3 points or higher.
Microbiology
The conventional swabs were plated on horse blood agar and incubated for at 
least 48 hrs at 37 ºC. To further increase the sensitivity of this method, the tips were 
also incubated in 10 ml brain heart infusion (BHI) broth on a shaker for 7 days at 37 
ºC.
The quantitative assay consisted of weighing the standardized bone sample 
and then homogenizing it in 50 ml PBS at high speed (15,000 rpm) for 2 minutes 
(Sorval Omnimix, Dupont Instruments, Newton, Connecticut, USA). Bacterial load was 
determined by serially diluting the homogenate, plating a standard volume (10 μl in 
triplicate) on blood agar and followed by incubation for 48 hrs at 37 ºC. The colonies 
were counted and bacterial load was calculated as the number of cfu’s per gram of 
bone tissue. After each run, the Omnimixer was thoroughly cleaned and subsequently 
sterilized to prevent any possible cross contamination between samples. The detection 
limit of this method was approximately 2.5 x 103 cfu /g bone depending on the mass of 
the speciﬁ c homogenized bone section. For statistical analysis, the negative samples 
(without growth of microorganisms) of the quantitative assay were considered to have 
the detection limit value (≈ 2.5 x 103 cfu /g bone) of bacterial load. Additionally, a 1 ml 
sample of bone homogenate was cultured in 10 ml BHI broth for 7 days at 37 °C in a 
shaker, to detect bacteria below the detection limit of the quantitative method.
Identiﬁ cation of S. aureus was based on the coagulase test (Staphytect®, 
Oxoid LTD, Basingstoke, Hamshire, UK). To genotype the strains, SmaI digests of total 
bacterial DNA were resolved by a pulsed-ﬁ eld gel electrophoresis (PGFE) performed as 
previously described by Ichiyama et al. (Ichiyama et al., 1991). Strains were considered 
clonal if less than two bands varied on a gel.
Histology
Bone slices were ﬁ xed in buffered formalin for two days, decalciﬁ ed in EDTA, 
embedded in parafﬁ n, mounted on slides and stained with haematoxylin and eosin. The 
disease severity score described by Smeltzer and co-workers was used to rate signs 
of infection (Smeltzer et al., 1997). This score is divided into four categories that are 
scored with zero to four points: intra-osseous acute-inﬂ ammation, intra-osseous chronic 
inﬂ ammation, periosteal inﬂ ammation and bone necrosis. The diagnosis of osteomyelitis 
was considered positive when the Smeltzer score was at least 4 points. The maximum 
score of sixteen signiﬁ es severe osteomyelitis with intra-medullar abscesses, ﬁ brosis 
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and multiple foci of sequestra. Slides were randomized and subsequently scored by an 
independent pathologist.
Statistical analysis
The results were analyzed using the Statistical Package for the Social 
Sciences (SPSS) version 10.1 for windows. The Mann-Whitney tests for independent 
samples were performed for comparison of the cfu count between groups, as 
these data were not normally distributed. This test was also used to test the ordinal 
radiological and histological score between different groups. The Wilcoxon Signed Rank 
test was performed for comparison of radiological scores within groups. Furthermore, 
ANOVA tests using Bonferroni’s post-Hoc test were performed for comparison of blood 
parameters between groups and paired student T-tests were performed for comparison 
of different time points within groups. Differences were considered signiﬁ cant at p < 
0.05.
Results
General
All animals tolerated both operations well, displaying no signs of systemic 
infection. One rabbit in the gentamicin-treated group had wound dehiscence after the 
second procedure. This wound was debrided, ﬂ ushed with physiological saline and 
subsequently closed subcutaneously, after which the rabbit recovered well. None of the 
rabbits developed soft tissue swelling or ﬁ stulae, clinically the infection was maintained 
in the tibia. 
The rabbits did display a tendency to slight weight loss after each procedure, 
recovering to normal after 7 to 14 days (Figure 2A). The initial weights were not 
signiﬁ cantly different from the weight at day 21 or day 42 except for the gentamicin 
group which showed an increase at day 21. Furthermore, there were no signiﬁ cant 
differences in weight between the different treatment regimens.
The pattern of changes in weight after each procedure are also reﬂ ected 
in the WBC (Figure 2B), which increased after each procedure and then returned to 
normal at day 21 and at day 42. The ESR showed a similar pattern although none of the 
changes were signiﬁ cant (data not shown). Both the WBC and the ESR patterns were 
seen in all treatment regimens.
The sham-treated group had a mean of 1.8 ± 1.1 g of wet bone cement 
injected. The hLF1-11 had 2.2 ± 0.2 g of wet bone cement injected, representing an 
mean total dose of 19.0 ± 1.8 mg hLF1-11/kg body weight. The gentamicin-treated 
animals had a similar amount of wet cement injected 2.4 ± 0.3 g, with a mean of 21.9 
± 2.3 mg gentamicin sulphate/kg body weight.
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Figure 2 A – B:  The changes in body weight and white blood cell (WBC) count 
 are plotted over time in Figures 2A and 2B respectively. The 
 ﬁ rst and second surgical procedure are indicated as OP1 and 
 OP2. There were no signiﬁ cant differences between groups. 
 Values are the means ± SD. 
Microbiology
The bacterial load per gram of bone is plotted in Figure 3. The median bacterial 
load of both the 3-week-control and the sham group was 1.3×105 and 2.4×106 cfu / g 
bone respectively. The hLF1-11 group had a signiﬁ cantly lower bacterial load (median of 
3.0×103 cfu/g bone) compared to both the control and sham group (p = 0.01). Seven 
out of eight animals did not have quantiﬁ able bacteria using this method. Furthermore, 
the gentamicin-treated animals also had a signiﬁ cantly lower bacterial load (median of 
2.7×103 cfu/g bone) compared to both the control and sham-treated group (p = 0.004). 
Two animals out of the eight gentamicin-treated animals still had quantiﬁ able bacteria in 
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their tibia. There was no signiﬁ cant difference in bacterial load between gentamicin- and 
hLF1-11-treated animals (p = 0.6). 
At autopsy, 2 out of 8 gentamicin-treated animals still yielded MRSA at autopsy. 
Similarly, MRSA was cultured in 3 out of 8 animals in the hLF1-11 group. On the other 
hand, MRSA was cultured from all ﬁ ve control animals. Moreover, all six sham-treated 
animals yielded MRSA after six weeks.
All bacteria isolated at autopsy were found to be coagulase positive. These 
S. aureus strains were subsequently also shown to be clonal (and identical to the strain 
which was used to induce the osteomyelitis) by PFGE, indicating that there was no 
contamination with other bacterial strains during the operative procedures.
Figure 3:  Quantitative microbiological analyses of the cultured bone 
 homogenate. The individual data points (circles), and the medians 
 (black bars) are indicated. The dotted line represents the approximate 
 detection limit (≈ 2.5 x 103 cfu/g bone) of the assay; animals below 
 this limit had negative cultures with the quantitative method 
 (no growth). Both the 3-week-control and the sham-treated animals 
 had a signiﬁ cantly higher bacterial load than the hLF1-11 (p = 0.01) 
 or gentamicin-treated animals (p = 0.004). There was no signiﬁ cant 
 difference in bacterial load between the 3-week-controls and 
 the sham-treated animals (p = 0.6) nor was there a difference 
 between the gentamicin- and hLF1-11-treated animals (p = 0.6).
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Radiology
The radiographs obtained at autopsy shown in Figure 4 illustrate the variety 
of disease severity found in this study. The average radiographical scores are plotted 
in Figure 5. The severity score for both the sham- and the gentamicin-treated animals 
increased signiﬁ cantly from day 21 to 42 (p = 0.039 and p = 0.011, respectively). 
In contrast, the score for the hLF1-11-treated animals did not increase (p = 0.29). 
Furthermore, at autopsy the score of the hLF1-11 group was also signiﬁ cantly lower 
than both the sham- and the gentamicin-treated group, p = 0.043 and p = 0.035 
respectively. In the control group 4, out of 5, and the sham-treated group 5, out of 6 
animals had a score higher than 3, indicating apparent osteomyelitis. In the gentamicin 
group, 5 out of 8 animals still had a score higher than 3 points, whereas in the hLF1-11-
treated animals only 3 out of 8 animals still had radiological signs of osteomyelitis.
Figure 4 A – D:  Representative radiographs of excised tibia’s. In the 3 week 
 control animal (A) periosteal reaction is visible (white 
 arrowheads). More severe signs of chronic osteomyelitis 
 are seen in the 6 week sham-treated animal (B). The periosteal 
 reaction (arrowheads) is exacerbated and a sequestrum is 
 present (arrows). Also, there is a ‘moth-eaten’ appearance 
 with bony destruction (stars). More proximal, there is 
 evidence of bone cement resorption (block arrows). Slight 
 periosteal elevation (arrowheads) was seen in the gentamicin-
 treated tibia (C) distal to the bone cement, whereas this hLF1-
 11-treated animal (D) did not show signs of osteomyelitis.
A B C D
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Figure 5:  The radiographic osteomyelitis score of Norden et al. was used to 
 analyze disease severity at day 21 (white bars) and day 42 (black 
 bars). The maximum score of seven reﬂ ects severe chronic 
 osteomyelitis in the entire tibia with periosteal new bone, sequestra 
 and foci of necrosis. The disease severity score increased from 
 day 21 to day 42 in both the sham group (p = 0.04) and the 
 gentamicin group (p = 0.011). Furthermore, at day 42, the hLF1-11-
 treated animals had a signiﬁ cantly better score than both the sham-
 treated (p = 0.043) and the gentamicin-treated animals (p=0.035). 
 Given are the mean values (± SD). 
Histology
Examples of the histological sections are shown in Figure 6, illustrating that 
disease severity varied considerably between animals. Some specimens displayed all 
signs of osteomyelitis; periosteal reaction, intra-medullary or sub-periosteal abscesses, 
sequestra and ﬁ brosis; as opposed to others that only had minor signs of osteomyelitis 
in the same group. 
This variation is reﬂ ected in the disease severity scores, which are plotted 
in Figure 7. However, both gentamicin and hLF1-11 signiﬁ cantly reduced the disease 
severity score compared to the sham and the control group (p = 0.04 and p = 0.01, 
respectively). There was neither a signiﬁ cant difference in disease severity score 
between hLF1-11 and gentamicin-treated animals nor between control and sham-treated 
animals.
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A histological score of 4 or more points was indicative of osteomyelitis 
(Smeltzer et al., 1997); this was seen in 4 out of 5 control animals and in 5 out of 6 
sham-treated animals. In the gentamicin-treated animals 3 out of 8 animals and in the 
hLF1-11 group only 2 out of 8 still had osteomyelitis based on the histological score 
alone.
Figure 6 A – D:  Representative photomicrographs (hematoxylin and eosin 
 stained) of transverse sections of the tibial cortex: Figure 6A 
 depicts a 3 week control animal, note the marked periosteal 
 reaction (stars) surrounding the largely necrotic cortex. Also 
 abscesses (white arrows) are present both intra-medullary 
 and sub-periosteally. The intra-medullary canal is ﬁ lled with 
 ﬁ brotic tissue (arrowheads) and some new bone formation 
 also can be seen (black arrow). Figure 6B depicts a sham-
 treated specimen. Note the bone marrow vs. bone cement 
 interface (white block arrows). Similar pathology can be 
 seen with periosteal bone formation (stars), abscesses (white 
 arrows), intra-medullary ﬁ brosis (arrowheads) and intra-
 medullary new bone formation (black arrows). Figure 
 6C shows a hLF1-11-treated specimen. Note the absence of 
 the periosteal inﬂ ammation (white arrows); no other 
 pathology can be seen. A gentamicin-treated specimen, 
 without periosteal inﬂ ammation (white arrows) is depicted in 
 Figure 6D. Magniﬁ cations: Figures 6A & 6B, 25 ×; Figures 
 6C & 6D, 50 ×.
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Figure 7:  Histo-pathological data as scored using the score of Smeltzer et 
 al. (mean + SD). The maximum score is 16 indicating severe 
 osteomyelitis with intra-medullary abscess and ﬁ brosis, severe 
 periosteal reaction with sub-periosteal abscess and multiple foci 
 of necrotic bone. Both the hLF1-11- and gentamicin-treated animals 
 have a signiﬁ cantly lower score than the 3 week control and the 
 sham group; p = 0.04 and p = 0.01 respectively.
Discussion
In this study, we induced chronic osteomyelitis in the tibia as described by 
Norden et al. (Norden et al., 1980). This model has been used extensively for evaluating 
experimental treatment protocols for osteomyelitis (Norden, 1988). We modiﬁ ed the 
treatment protocol by local debridement and subsequent injection of calcium phosphate 
cement containing the  antimicrobial agent. The pathogen used in this study is an MRSA 
strain isolated from a patient with osteomyelitis, that had been used in a previous 
osteomyelitis study and shown to be sufﬁ ciently virulent (personal communication, Dr. 
U. Joosten). 
MRSA was recovered from all control and sham-treated animals. However, in 
both groups, one animal each had a low bacterial load, which was also reﬂ ected in their 
radiological and histological score. Since the ‘golden standard’ for osteomyelitis was a 
positive culture for MRSA, we concluded that our model was valid, with a 100% infection 
rate in both the control and the sham-treated group (no antibiotic).
Regarding the hLF1-11 group, in 5 out of 8 animals no bacterial growth was 
detectable, and of the 3 MRSA positive rabbits only one animal was found to have a high 
bacterial load. In addition this rabbit also had an initial high radiological score of 5.5 
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at the onset of treatment. The other two rabbits did not have quantiﬁ able bacteria, but 
showed growth of MRSA in the broth culture, and also had radiological and histological 
signs of osteomyelitis. 
In the gentamicin group, 5 out of 8 animals were still found to have radiological 
osteomyelitis and 3 out of 8 animals had histological signs of infection. Only 2 of these 
animals had positive cultures for MRSA. Since radiological signs were seen distal of the 
bone cement, it is suggested that the infection survived in the distal diaphysis, a location 
at which gentamicin levels could be substantially lower (Wahlig et al., 1978). Some 
osteomyelitis signs may have been missed on histology, as only sections at one level 
next to the bone cement were examined, whereas radiology picked up osteomyelitis 
signs of the entire femur. The two methods supplemented each other, allowing reliable 
interpretation of the data. 
Nibbering et al. found a 2.5 log reduction of bacterial load in the mouse thigh 
model using very low systemic dosages of hLF1-11 (0.1 – 1 nmole) (Nibbering et al., 
2001). An immune-inciting effect was presumed to be responsible for the reduction of 
bacterial load in this mouse thigh model (Nibbering et al., 2001), whereas the direct 
killing effect of higher concentrations hLF1-11 is presumed to play a role in the efﬁ cacy 
of hLF1-11 in the prophylactic osteomyelitis rabbit model (Stallmann et al., 2004). In 
this study both mechanisms may have acted simultaneously; rapid bacterial killing 
occurring at the level of the tibia and due to the bone-serum gradient, low systemic 
concentrations of hLF1-11 could then incite an immune response (Wahlig et al., 1978). 
However, more pharmaco-kinetic studies are required to elucidate the mechanism of 
action in this model.
A disadvantage of local delivery of conventional antibiotics is the low level sub-
inhibitory release after the burst release has subsided. This phenomena is well-known 
to occur in the case of gentamicin release from PMMA and release can even continue 
for years thereby also inducing/selecting antimicrobial resistance of bacteria (Neut et 
al., 2001; Neut et al., 2003; van de Belt et al., 1999; von Eiff et al., 1997). However, 
the advantage of AMPs is their intrinsic low tendency to induce resistance, despite 
prolonged passages of bacteria through sub-inhibitory concentrations (Giacometti et 
al., 2002; Hancock, 1997; Zasloff, 2002). Furthermore, we used a resorbable cement, 
which ensures that the antibiotic can not be released indeﬁ nitely (Ooms et al., 2002).
Over the past decade numerous naturally occurring AMPs have been identiﬁ ed 
emphasizing their pivotal role as part of the ﬁ rst line defense in our innate immune 
system (Hancock, 1997; Zasloff, 2002). Several research groups have speciﬁ cally 
described options for the development of AMPs as new antimicrobial agents and 
investigated their efﬁ cacy in vivo. Van ‘t Hof et al. have reviewed a large number of 
AMPs currently under investigation (van ‘t Hof et al., 2001). The rBPI21 antimicrobial 
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peptide has reached phase III clinical trials and has shown promising clinical results: 
improving the outcome of meningococcal sepsis in children (Levin et al., 2000). The 
rise of antimicrobial resistance has further emphasized the need for new antimicrobial 
agents. MRSA has already emerged in large areas of the world, and with the additional 
increase of infections due to S. aureus with reduced susceptibility or resistance to 
glycopetides, the concern about the development of strains resistant to all available 
antibiotics has aroused. (Whitener et al., 2004).
This study demonstrates the ability of hLF1-11 incorporated into calcium 
phosphate cement to treat an MRSA osteomyelitis in rabbits. hLF1-11 improved the 
clinical outcome radiologically, microbiologically and histologically compared to control 
animals. Furthermore, the efﬁ cacy of hLF1-11 was comparable to that of gentamicin in 
this model. The results of this study thus warrant further pre-clinical investigations into 
the use of hLF1-11 for the treatment of osteomyelitis.
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Background
Osteomyelitis has long been the most feared and difﬁ cult to treat complication 
in orthopaedic surgery. The etiology being endogenous (hematogenic), exogenous 
(complicated fractures or surgery) or by neighboring decubitical wounds. The causative 
organism is mostly S. aureus or S. epidermidis (> 80%). In chronic osteomyelitis the 
vascularization is progressively compromised by ﬁ brosis resulting in the isolation of the 
effected segment (Walenkamp et al., 1998). The treatment of osteomyelitis is therefore 
based on three mainstays: debridement, reconstruction with adequate stabilization and 
antibiotic therapy. 
The debridement needs to be thoroughly to remove all devascularized bone, 
as this acts as a foreign body on which bacteria can retreat in their protective glycocalyx 
(Gristina, 1987). Additionally, all possible foreign material should be removed. Radical 
surgical debridement can result in large bone and soft tissue defects. These defects 
should be reconstructed where possible with autologous bone. The soft tissue defect 
can be treated with a vascularized muscle ﬂ ap improving blood ﬂ ow to the affected 
area. From clinical experience it is also known that stabilization improves outcome of 
treatment (Walenkamp et al., 1998). Stability is preferably achieved with the use of an 
external ﬁ xator, thereby avoiding foreign body at the infected site.
Antibiotics augment the surgical approach of osteomyelitis. The antibiotic 
approach is twofold: systemic administration and antibiotic beads. Systemic antibiotics 
are indicated for the treatment of sepsis and soft tissue infection. In general, antibiotics 
should be prescribed for 6 to 12 weeks after initial treatment (Walenkamp et al., 1998). 
Secondly, antibiotics can be applied locally incorporated into beads. Buchholz ﬁ rst 
described the release of antibiotics from PMMA bone cement (Buchholz et al., 1970), 
thereby heralding a new age in both the treatment and prevention of osteomyelitis. 
Ever since, authors have studied different antibiotic combinations with all sorts of 
bone cements. More recently the resorbable calcium phosphate cements and collagen 
ﬂ eeces have been added to these studies (Kanellakopoulou et al., 2000). Their clinical 
indications are not described as well as for the gentamicin beads.
Wahlig demonstrated that gentamicin beads produce high local antibiotic 
tissue levels in dogs (Wahlig et al., 1978). Walenkamp conﬁ rmed this ﬁ nding for humans, 
showing local gentamicin levels exceeding 100 μg/ml (Walenkamp et al., 1986). On the 
contrary, serum levels were almost below the detection limit and adverse toxic events 
were not seen (Walenkamp et al., 1986). These high local tissue levels are effective even 
to resistant bacteria (MIC > 4 μg/ml) as the resistance is usually based on non-toxic 
systemic concentration (Walenkamp et al., 1986). Von Eiff et. al. isolated gentamicin 
resistant small colony variants of S. aureus from patients treated with gentamicin beads 
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from tissue samples; recurrence of osteomyelitis correlated with the presence of the 
small colony variants (von Eiff et al., 1997). Additionally, Neut et al. published a paper 
on the presence of resistant bacteria on gentamicin beads (Neut et al., 2001).
Besides the use of gentamicin in beads, it has also long been incorporated 
into PMMA bone cement and is used extensively in clinical practice. Currently there is 
some debate whether this prophylactic use is desirable. Gentamicin containing bone 
cement is known to elude low levels of gentamicin for several years which can result in 
patients becoming a carrier of resistant bacteria (van de Belt, 2001). The short term 
advantage of gentamicin-containing bone cement could not be sustained in the long ten 
year follow-up study (Josefsson et al., 1993).
The debate on desirability of gentamicin-containing bone cement is now 
complicated by the emergence of resistant bacteria in the community. MRSA is now 
widely spread in the western world, with prevalence rates even up to 50 % (ﬁ gure 1) 
(RIVM, 2004).
 Fortunately the Netherlands has been exempted from this high prevalence, 
however, the incidence is on rise (RIVM, 2004). Additionally, there are reports on S. aureus 
strains with reduced sensitivity to vancomycin and even resistance has been reported 
(Cepeda et al., 2004; Whitener et al., 2004). MRSA infection is generally controlled with 
vancomycin or teicoplanin and only very recently were the oxazolidinones (amoungst 
which linezolid) added to the pharmaceutical armentarium (Giannoudis et al., 2005). 
The discovery of this antibiotic class has been very important in providing an antibiotic 
‘back-up’ strategy when conventional therapy fails (Giannoudis et al., 2005). Despite the 
great need for new superior antimicrobial substances, there are close to zero in the 
pipelines of the large drug companies (Livermore, 2005; Projan et al., 2004). 
106
Chapter 7
Figure 1:  Staphylococcus aureus: proportion of invasive isolates resistant to 
 oxacillin (equivalents) in 2004 (RIVM, 2004)
In the past decade antimicrobial peptides have been investigated by many 
authors as a potential source for new antimicrobial drugs (Hancock, 1997; Van’t Hof 
et al., 2001). The AMPs are a fundamental part of the evolutionary immune system, 
enabling all species to repel microorganisms immediately, thus preventing them from 
being overgrown by microorganisms (Zasloff, 2002). The numbers of AMPs available 
as potential antimicrobial substances is almost endless. They are discovered in every 
tissue, bodily ﬂ uids or cells investigated, for example in the slime of toads, human 
sweat, tears, skin, intestine, saliva, milk, neutrophils, macrophages and so on (Nibbering 
et al., 2001; Van’t Hof et al., 2001; Zasloff, 2002). Another advantage is their intrinsic 
low tendency to induce antimicrobial resistance. This property was demonstrated by 
prolonged passages of bacteria through sub-inhibitory concentrations (Giacometti et 
al., 2002; Hancock, 1997; Zasloff, 2002).
Our research efforts have focused on two antimicrobial peptides, Dhvar-5 and 
hLF1-11. Dhvar-5 is an 14 amino acid peptide based on the amino acid composition 
of histatin-5 (Van’t Hof et al., 2001). The Dhvar-5 molecule has both fungicidal and 
bactericidal activity in vitro against among others MRSA (Lyaruu et al., 2000; Ruissen et 
al., 2001). The antimicrobial peptide human Lactoferrin 1-11 (hLF1-11) is derived from 
the active domain of human lactoferrin (N-terminal amino acids 1-11) (Lupetti et al., 
2000). hLF1-11 has a broad antimicrobial spectrum in vitro against both bacteria and 
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fungi (Lupetti et al., 2000; Lupetti et al., 2003b; Nibbering et al., 2001). Furthermore, 
Nibbering et al. demonstrated the efﬁ cacy of hLF1-11 in vivo, reducing the number 
of MRSA bacteria after systemic administration in the mouse thigh infection model 
(Nibbering et al., 2001).
Discussion of the obtained data
In chapters 2 and 3 we investigated the release of Dhvar-5 and gentamicin 
from standard commercially available bone cement, Osteopal® and Osteopal G® (Biomet 
Merck, Darmstadt, Germany). As these were in vitro studies, the release pattern in vivo 
could be very different compared to our standardized protocol. However, these studies 
did clearly demonstrate that it is possible to disperse an antimicrobial peptide in PMMA 
resulting in reproducible release patterns. Furthermore, we also conﬁ rmed the activity 
of the peptide after release with a standardized killing assay.
The release patterns of Dhvar-5 yielded two unexpected results, the ﬁ rst one 
being an abnormally high release of peptide (70-91%) compared to what is described 
for gentamicin in the literature (Faber et al., 2003; Kuhn, 2000). Secondly, the addition 
of Dhvar-5 to gentamicin-containing PMMA bone cement increased gentamicin release 
fourfold (Faber et al., 2005a).
In chapter 4, we investigated the micro-architectural structure of the PMMA 
bone cement containing Dhvar-5 and/or gentamicin. Scanning electron microscopy 
revealed a rougher freeze fracture pattern for PMMA cement with Dhvar-5 as opposed to 
cement containing only gentamicin or no additives. It also showed more empty imprints 
of dissolved gentamicin sulphate crystals by the addition of Dhvar-5. We further tried 
to quantify the porosity with the mercury intrusion method. The differences in porosity 
were only minor with the addition of only Dhvar-5, suggesting the pore range would 
be below the detection limit. However, in the gentamicin containing cements we did 
demonstrate the presence of more empty voids with increasing Dhvar-5 additives. This 
ﬁ nding suggests a very small porous network, allowing for the dissolution of gentamicin 
crystals further from the surface. However, there is only circumstantial evidence for the 
existence of this network, as it could not be visualized or measured directly.
In the second part of chapter 4 the compressive strength of PMMA bone 
cement with both Dhvar-5 and gentamicin is reported. We wanted to know whether the 
admixture of Dhvar-5 would preclude use to non-weight bearing applications. The results 
showed a decrease of compressive strength in the presence of Dhvar-5, but did meet 
the ISO 5833 standard requirement with respect to compressive strength. However, we 
would not recommend weight bearing application until all other mechanical properties 
(tensile and fatigue strength) have been vigorously tested.
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In chapter 5 we tested the efﬁ cacy of Dhvar-5 mini-beads in vivo and compared 
its efﬁ cacy to gentamicin in a MRSA osteomyelitis prevention model. All the infection 
prevention models have the disadvantage of an abnormal high bacterial load which 
is introduced initially. However, it does provide critical data on dose ﬁ nding and the 
proof of principle. Our osteomyelitis prevention model was modiﬁ ed from the original 
(Nijhof et al., 2000). The MRSA strain (ATCC: BAA-811) was not previously tested in 
an osteomyelitis model, although it was isolated from an osteomyelitis patient. To 
ensure a 100% infection rate in the sham group we increased the inoculum to 107 cfu. 
Furthermore, we used a bead chain instead of ﬁ lling the entire canal with bone cement. 
A major advantage of this method is the exact controllable amount of cement (and 
antibiotic agent) which is introduced. However, the disadvantage is that a ‘dead space’ 
remains between beads and femur. 
The results showed that Dhvar-5 reduced bacterial counts signiﬁ cantly, falling 
short, however, in sterilizing bone samples. Gentamicin, on the contrary,  was able to 
reduce bacterial counts signiﬁ cantly more than Dhvar-5, and also managed to sterilize 
more than 50% of the femurs, despite marked gentamicin resistance (MIC = 256 μg/
ml). This disappointing result is probably attributable to the unknown pharmacokinetic 
factors of Dhvar-5. The half life of some AMPs is known to be much shorter than that 
of gentamicin (Nibbering et al., 2001). Wang et al. described one AMP being bound 
to serum proteins also resulting in reduced antimicrobial activity (Wang et al., 2004). 
Den Hertog et al. found that Dhvar-5 is readily degraded by proteolytic enzymes as 
trypsin (den Hertog et al., 2004). These factors could all account for lower levels of 
biologically active Dhvar-5 at the infection site as opposed to our calculations from the 
release data (Faber et al., 2003). Further research into the pharmacokinetics could be 
the key to ﬁ nding an AMP which can compete with or even exceed the performance of 
conventional antibiotics.
Stallmann et al. have shown that hLF1-11 could be released from different 
calcium phosphate bone cements and that it was able to prevent osteomyelitis in vivo 
(Stallmann et al., 2003; Stallmann et al., 2004). Therefore, in chapter 6 we proceeded 
to investigate whether hLF1-11 incorporated into calcium phosphate cement could 
also be effective in a chronic MRSA osteomyelitis treatment model. We used the well 
described model of Norden (Norden et al., 1980). It was modiﬁ ed to include a thorough 
debridement and injection of the self setting cement after an initial incubation period of 
3 weeks, thereby further augmenting to its clinical relevance.
The results showed that hLF1-11 was as effective in treating MRSA 
osteomyelitis as gentamicin. The MRSA strain (W234) we used was, however, sensitive 
to gentamicin. The W234 strain was selected because it was known to be more virulent 
than the MRSA strain (ATCC: BAA-811) used in chapter 5 (personal communication Dr. 
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U. Joosten). This allowed us to reduce the inoculum dose and increase the reliability 
of the model. However, it could be that hLF1-11 has a better efﬁ cacy than gentamicin 
against a S. aureus truly resistant to gentamicin.
Future prospective
The problem of antibiotic resistant bacteria is expected to increase and could 
potentially threaten our ability to treat infections (Livermore, 2005). Traditionally the 
multinational pharmaceutical companies have been pursuing new antimicrobial agents, 
however, over the past decade interest has faded (Projan et al., 2004). This has resulted 
in only a few new antibiotics being introduced to the clinic since the 1980s, (Norrby et 
al., 2005). It is obvious that the stagnation of this development could eventually pose 
a threat to public health. There is a desperate need to re-invigorate the search for 
new antimicrobial substances, especially targeted to resistant bacteria (Norrby et al., 
2005).
It is well possible that amongst the large group of antimicrobial peptides 
(> 1000) suitable drug candidates can be found that can treat resistant infections 
(Hancock, 1997; Zasloff, 2002). In order to facilitate future research of AMPs, it is vital 
to ﬁ nd a reliable screening method for therapeutic potential. This would greatly speed 
up and enhance the chance of ﬁ nding a therapeutic AMP against resistant bacteria.
In our studies we showed the ability of Dhvar-5 to reduce bacterial counts 
in vivo. However, the data clearly show that gentamicin was superior in preventing 
osteomyelitis in our model. The high local concentrations released by the bone 
cement render it unlikely that Dhvar-5 would be more effective with a different mode of 
administration. Furthermore, we also demonstrated that Dhvar-5 can induce hemolysis 
and bone cell death in vitro at high concentrations (Stallmann et al., 2005). Future 
research should be directed to a better understanding of the pharmacokinetic factors 
involved and modifying Dhvar-5 to reduce toxicity.
However, the antimicrobial peptide hLF1-11 did not show any of these 
toxic effects in vitro (Stallmann et al., 2005). Furthermore, the peptide has a very 
good track record in vivo, with high activity against multidrug resistant S. aureus and 
multidrug resistant A. baumannii in mice (Dijkshoorn et al., 2004; Nibbering et al., 
2001), and excellent performance in both prevention and treatment of osteomyelitis in 
rabbits (Faber et al., 2005b; Stallmann et al., 2004). hLF1-11 has great potential as 
an antibiotic substance both incorporated into calcium phosphate cement and as an 
injectable antibiotic. Future research should focus on the best mode of administration, 
dose ﬁ nding, and possible combinations with other antibiotics (Lupetti et al., 2003a), 
cheap manufacture, and ultimately pre-clinical testing.
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Achtergrond
Osteomyelitis (botontsteking) is een van de meest gevreesde complicaties 
in de orthopedie, de therapie veroorzaakt veel morbiditeit en de uitkomst is allerminst 
zeker. De etiologie is zowel endogeen (via de bloedbaan), als exogeen (via open 
fracturen of chirurgische ingreep) of per continuüm (vanuit een aangrenzend huiddefect). 
De causale micro-organismen zijn vooral S. aureus en S. epidermidis (>80%). In 
chronische osteomyelitis wordt de vascularisatie (doorbloeding) progressief bedreigd 
door bindweefselvorming (ﬁ brose), waardoor een botsegment geïsoleerd kan raken 
en een sekwester (afgestorven botstuk) ontstaat (Walenkamp 1998). De behandeling 
van osteomyelitis is gebaseerd op drie peilers: 1. radicaal chirurgisch debridement 
(operatief verwijderen van dood weefsel), 2. reconstructie met adequate stabilisatie 
(operatie gericht op herstel en vastzetten van bot) en 3. antimicrobiële therapie.
Het debridement moet zeer grondig geschieden met verwijdering van al het 
gedevasculariseerde bot, omdat dit fungeert als een vreemd lichaam waarop micro-
organismen zich kunnen nestelen en zich vervolgens terug trekken in de glycocalyx 
(beschermende slijmlaag op het vreemde lichaam) (Gristina, 1987). Tevens dienen alle 
andere corpora aliena verwijderd te worden. Door het radicale chirurgische debridement 
kunnen grote defecten ontstaan in botweefsel en weke delen (omringende weefsel en 
huid). Deze defecten dienen zo mogelijk te worden gereconstrueerd met autoloog 
(lichaams eigen) bot. De defecten van de weke delen kunnen met een gesteelde of 
vrije ﬂ ap (van bloedvaten voorzien transplantaat) worden gereconstrueerd zodat de 
vascularisatie naar het aangedane gebied wordt geoptimaliseerd. Uit klinische ervaring 
is gebleken dat goede stabilisatie leidt tot een beter resultaat (Walenkamp, 1998). De 
stabiliteit wordt bij voorkeur verkregen door middel van een ﬁ xateur externe (uitwendig 
constructie om botdelen vast te zetten), zodat er geen vreemd lichaam ter plaatse van 
de infectiehaard achterblijft.
Antimicrobiële therapie is een belangrijke aanvulling op de chirurgische 
behandeling van osteomyelitis. De antibiotica worden zowel systemisch (via de bloedbaan) 
als lokaal toegediend. Systemische antibiotica zijn geïndiceerd bij de behandeling van 
sepsis en van infectie van de weke delen en dienen voor een periode van 6 tot 12 weken 
te worden voorgeschreven (Walenkamp, 1998). De lokale behandeling bestaat uit 
antimicrobiële kralen ter plaatse van de infectie. Buchholz beschreef als eerste de afgifte 
van antibiotica uit botcement bestaande uit polymethylmethacrylaat (PMMA) (Buchholz 
1970). Sindsdien hebben vele auteurs verschillende antibiotica met allerlei botcementen 
gecombineerd. Recent zijn aan deze studies resorbeerbare calciumfosfaatcementen en 
collageenmatjes toegevoegd (Kanellakopoulou et al., 2000). 
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Wahlig et al. toonden aan dat met gentamicinekralen (een aminoglycoside 
antibioticum) zeer hoge lokale weefselspiegels konden worden verkregen bij schapen 
(Wahlig et al., 1978). Walenkamp et al. bevestigden deze bevinding in mensen: 
gentamicinespiegels in wondvocht bereikten meer dan 100 μg/ml terwijl bloedspiegels 
nauwelijks meetbaar waren (Walenkamp et al., 1986). Derhalve werden toxische effecten 
van gentamicine  dan ook niet waargenomen. Door de hoge lokale concentraties werden 
resistente bacteriën (MIC-waarde > 4 μg gentamicine/ml) effectief behandeld, daar 
deze MIC-waarde is gebaseerd op systemische en niet op toxische weefselspiegels 
(Walenkamp et al., 1986). Von Eiff et al. isoleerden echter zogenaamde ‘small colony’ 
bacterie-varianten van patiënten behandeld met gentamicinekralen. Een recidief van 
osteomyelitis correleerde met de aanwezigheid van deze varianten (von Eiff et al., 
1997). Ook demonstreerden Neut et al. de aanwezigheid van bacteriën op gentamicine 
kralen (Neut et a.l., 2001).
Naast het gebruik van gentamicine in kralen voor de behandeling van 
osteomyelitis wordt gentamicine eveneens op grote schaal profylactisch gebruikt in 
PMMA botcement. In de literatuur is er een discussie gaande over de wenselijkheid van 
dit profylactische gebruik. Van gentamicine botcement is bekend dat het langdurig zeer 
lage hoeveelheden gentamicine afgeeft. Dit resulteert er in dat patiënten drager kunnen 
worden van resistente bacteriën (van de Belt, 2001). Daarnaast kan het korte termijn 
voordeel van gentamicine-houdend botcement niet worden gehandhaafd in een lange 
‘follow-up’ van tien jaar (Josefsson and Kolmert, 1993).
De discussie over gentamicine-houdend botcement wordt nu bemoeilijkt 
door de toegenomen prevalentie van resistente bacteriën. De prevalentie van MRSA 
(methicylline resistente S. aureus) bedraagt in sommige westerse landen meer dan 50% 
(RIVM, 2004). De prevalentie in Nederland is gelukkig laag, echter deze is wel stijgende. 
Daarnaast zijn er nu rapportages van verscheidene S. aureus stammen met afgenomen 
sensitiviteit en zelfs resistentie voor vancomycine (Cepeda et al., 2004; Whitener 
et al., 2004). MRSA infectie wordt over het algemeen behandeld met vancomycine 
of teicoplanine en pas zeer recent zijn de oxazolidinonen (een groep antibacteriële 
middelen, waaronder linezolid) toegevoegd aan het farmaceutische arsenaal (Giannoudis 
et al., 2005). De ontdekking van deze antibacteriële groep is zeer belangrijk geweest 
als ‘back-up’-behandeling wanneer conventionele antibiotica falen, bijvoorbeeld in het 
geval van vancomycine resistente infecties (Giannoudis et al., 2005). Ondanks de grote 
behoefte aan nieuwe en betere antimicrobiële middelen, zijn er momenteel nauwelijks 
nieuwe antibiotica in ontwikkeling bij de grote farmaceutische bedrijven (Livermore, 
2005; Projan and Shlaes, 2004).
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Aangeboren immuunsysteem
Het afgelopen decennium zijn de antimicrobiële peptiden (AMPs) onderzocht 
door vele auteurs als mogelijke bron voor nieuwe antibiotica (Hancock, 1997; van ‘t Hof 
et al., 2001). AMPs zijn een basaal onderdeel van het evolutionaire immuunsysteem in 
alle gewervelde en ongewervelde dieren, waardoor deze in staat worden gesteld om 
direct micro-organismen te bestrijden (Zasloff, 2002). Het aantal antimicrobiële peptiden 
en eiwitten lijkt onbeperkt. AMPs zijn inmiddels ontdekt in alle onderzochte weefsels, 
cellen en afscheidingsvochten, bijvoorbeeld slijm van padden, menselijk zweet, tranen, 
huid, maagdarmkanaal, speeksel, melk, afweercellen etc. (Nibbering et al., 2001; van 
‘t Hof et al., 2001; Zasloff, 2002). Daarnaast blijken AMPs de intrinsieke eigenschap te 
hebben om minimaal resistentie te induceren. Dit werd aangetoond door bacteriën bloot 
te stellen aan zeer lage concentraties gedurende langere tijd, waarbij geen resistentie 
optrad (Giacometti et al., 2002; Hancock, 1997; Zasloff, 2002).
Ons onderzoek richtte zich op twee antimicrobiële peptiden, Dhvar-5 en hLF1-
11. Dhvar-5  bestaat uit 14 aminozuren en is gebaseerd op de aminozuurcompositie 
van histatine-5, dat in humaan speeksel voorkomt (van ‘t Hof et al., 2001). Dhvar-5 
heeft zowel antifungale (anti-schimmel) als antibacteriële eigenschappen in vitro tegen 
ondermeer MRSA (Lyaruu et al., 2000; Ruissen et al., 2001). Het antimicrobiële peptide 
humaan lactoferrine 1-11 (hLF1-11) is afkomstig van het actieve domein van humaan 
lactoferrine (N-terminale aminozuren 1-11) in speeksel en moedermelk (Lupetti et al., 
2000). hLF1-11 heeft een breed antimicrobieel spectrum en is in vitro actief tegen 
zowel schimmels als bacteriën (Lupetti et al., 2000 en 2003; Nibbering et al., 2001). 
Ook demonstreerden Nibbering et al. de effectiviteit van hLF1-11 in vivo, waarbij het 
aantal MRSA bacteriën signiﬁ cant verlaagd werd in het muizen dijbeen, wanneer in de 
bloedbaan hLF1-11 werd ingespoten (Nibbering et al., 2001). Aangetoond werd dat 
hLF1-11 zich speciﬁ ek kan binden aan bacteriën die elders in het lichaam aanwezig zijn 
en deze bacteriën effectief kan doden.
Discussie van de verkregen gegevens
In de hoofdstukken 2 en 3 hebben wij de afgifte van Dhvar-5 en gentamicine 
uit standaard commercieel verkrijgbaar PMMA botcement, Osteopal® and Osteopal G® 
(Biomet Merck, Darmstadt, Duitsland) beschreven. Daar dit in vitro studies betroffen 
is het mogelijk dat de afgiftepatronen in vivo verschillen van ons model. Onze studies 
toonden duidelijk aan dat het mogelijk is om een antimicrobieel peptide te vermengen 
met PMMA botcement en dat dit resulteert in reproduceerbare afgiftepatronen. Tevens 
werd de antimicrobiële activiteit van Dhvar-5 aangetoond na afgifte uit het PMMA 
botcement. 
119
Samenvatting en discussie
De afgiftepatronen van Dhvar-5 toonden twee onverwachte bevindingen: 
Allereerst werd een zeer hoog percentage van het peptide afgegeven (70-91%) in 
vergelijking met de afgifte beschreven voor gentamicine (Faber et al., 2003; Kuhn, 
2000). Ten tweede werd de afgifte van gentamicine verviervoudigd door de toevoeging 
van Dhvar-5 aan PMMA botcement (Faber et al., 2005a).
In hoofdstuk 4 werd de microstructuur van PMMA botcement met Dhvar-5 en 
gentamicine onderzocht. Elektronenmicroscopie toonde een veel grover ‘freeze fracture’ 
(in vloeibaar stikstof bevroren breukoppervlak) patroon aan voor PMMA botcement met 
Dhvar-5 dan voor PMMA botcement met alleen gentamicine of PMMA zonder additieven. 
Daarnaast werden meer ‘lege afdrukken’ van opgeloste gentamicinekristallen (na 
afgifte) aangetroffen in PMMA botcement met Dhvar-5. Getracht werd de porositeit 
(doorlaatbaarheid) te kwantiﬁ ceren met de ‘mercury intrusion’ methode (waarbij met 
hoge druk kwik wordt ingespoten). De verschillen in porositeit waren zeer klein, wat 
suggereert dat de poriegrootte mogelijk kleiner is dan de detectie limiet. Wel werden 
in de gentamicine-houdende cementen meer lege lacunes (kleine holten) gevonden 
naarmate meer Dhvar-5 aan deze cementen was toegevoegd. Deze bevindingen 
suggereren de aanwezigheid van een zeer klein poreus netwerk waardoor gentamicine 
kristallen verder van de oppervlakte kunnen oplossen in de aanwezigheid van Dhvar-5. 
Hierbij moet worden aangetekend dat er alleen indirect bewijs is voor het bestaan van 
dit netwerk aangezien we dit niet met de ‘mercury intrusion’ methode hebben kunnen 
aantonen.
In het tweede deel van hoofdstuk 4 werd de compressiesterkte van 
PMMA botcement met zowel Dhvar-5 als gentamicine onderzocht. Wij wilden weten 
of de toevoeging van Dhvar-5 zou leiden tot een verzwakking van het botcement, 
waardoor toepassing beperkt blijft tot antibioticakralen en niet voor gewichtsdragende 
toepassingen. De resultaten toonden dat de compressiesterkte inderdaad daalde met 
de toevoeging van Dhvar-5. De sterkte voldeed echter wel aan de ISO 5833 standaard 
(de internationale standaard waaraan botcementen moeten voldoen). Hierbij moet in acht 
worden genomen dat andere mechanische eigenschappen (o.a. buig- en treksterkte) niet 
zijn onderzocht en dat wij gebruik voor gewichtsdragende toepassingen pas aanbevelen 
nadat deze eigenschappen ook uitgebreid zijn getest.
In hoofdstuk 5 werd de effectiviteit van Dhvar-5 mini-kralen in vivo getest 
en vergeleken met gentamicine in een MRSA osteomyelitis preventiemodel. In het 
algemeen hebben infectie preventiemodellen het nadeel dat initieel onnatuurlijk hoge 
aantallen bacteriën worden ingebracht. Deze studies leveren echter wel essentiële data 
voor het aantonen van het werkingsprincipe en het vinden van de juiste dosering. Ons 
osteomyelitismodel werd op een aantal punten aangepast van het oorspronkelijke model 
(Nijhof et al., 2000). De MRSA stam (ATCC: BAA-811), afkomstig van een osteomyelitis 
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patiënt, is niet eerder gebruikt in een osteomyelitismodel. Om een 100% infectie 
percentage veilig te stellen werd een groter aantal bacteriën (107 cfu) toegediend. 
Daarnaast werd een antibioticumkralenketting gebruikt in plaats van het hele kanaal 
te vullen met botcement. Het grote voordeel van onze methode is dat er een exact 
gecontroleerde hoeveelheid botcement (en dus antibioticum) wordt ingebracht. Hier 
tegenover staat dat er een dode ruimte overblijft tussen de kralen en het botcement, 
maar dit heeft wel als bijkomend voordeel dat  het afgifte-oppervlak wordt vergroot.
De resultaten toonden dat Dhvar-5 het aantal vitale bacteriën signiﬁ cant 
verlaagde, maar geen van de femora (dijbenen) werd echter volledig gesteriliseerd. 
Gentamicine verlaagde het aantal vitale bacteriën signiﬁ cant meer en steriliseerde de 
helft van de femora ondanks de zeer sterke resistentie van de MRSA stam (MIC-waarde 
= 256 μg/ml).
Dit enigszins teleurstellende resultaat werd waarschijnlijk veroorzaakt door 
onbekende farmacokinetische eigenschappen van Dhvar-5. De halfwaarde tijd van 
sommige AMPs is veel korter dan de halfwaarde tijd van gentamicine (Nibbering et 
al., 2001). Wang et al. beschreven een AMP welke zich bindt aan serumeiwitten, wat 
resulteerde in een verminderde antimicrobiële werking (Wang et al., 2004). Den Hertog et 
al. toonden aan dat Dhvar-5 gemakkelijk wordt afgebroken door proteolytische enzymen 
zoals trypsine (Den Hertog et al., 2004). Deze factoren zouden kunnen leiden tot een 
lagere hoeveelheid biologisch actief Dhvar-5 ter plaatse van de infectie dan wij hadden 
berekend op basis van de afgifte data (Faber et al., 2003). Verder onderzoek naar de 
farmacokinetische eigenschappen zou de sleutel kunnen zijn tot het vinden van een AMP 
dat de werking van conventionele antibiotica kan evenaren of zelfs verbeteren.
Stallmann et al. demonstreerden dat hLF1-11 niet alleen kan worden afgegeven 
uit verschillende calciumfosfaat botcementen in vitro, maar dat het ook effectief was 
om osteomyelitis te voorkomen in vivo (Stallmann et al., 2003 en 2004). In hoofdstuk 
6 werd hier vervolg aangegeven door de effectiviteit van hLF1-11 in combinatie met 
calciumfosfaat botcement te onderzoeken in een chronisch MRSA osteomyelitis 
behandelmodel. Het veelvuldig gebruikte model van Norden et al., waarbij osteomyelitis 
met systhemische antibiotica wordt behandeld, hebben we hiervoor op een aantal 
punten gemodiﬁ ceerd (Norden et al., 1980). Na de initiële incubatieperiode van 3 weken 
werd een zorgvuldig debridement uitgevoerd en werd vervolgens een zelf-uithardend 
cement geïnjecteerd. Hierdoor werd eveneens de klinische relevantie verbeterd.
De resultaten lieten zien dat hLF1-11 vergelijkbare effectiviteit had tegen MRSA 
osteomyelitis als gentamicine. De gebruikte MRSA stam (W234) was echter gevoelig 
voor gentamicine. Toch werd voor de W234 stam gekozen daar bekend was dat deze 
stam een hogere virulentie bezit dan de MRSA stam (ATCC: BAA-811) die in hoofdstuk 
5 werd gebruikt (persoonlijke informatie Dr. U. Joosten). Hierdoor werd het mogelijk 
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om zowel de hoeveelheid bacteriën te verlagen in het inoculum als de betrouwbaarheid 
van het model te verhogen. Het is te verwachten dat hLF1-11 een betere effectiviteit 
heeft dan gentamicine als een gentamicine-resistente S. aureus stam was gebruikt.
Toekomst perspectief
Het probleem van antibiotica-resistente bacteriën zal naar verwachting alleen 
maar toenemen en vormt een serieuze bedreiging voor de huidige behandeling van 
infecties (Livermore, 2005). Traditioneel werden antimicrobiële middelen ontwikkeld 
door de grote farmaceutische bedrijven. Tijdens het afgelopen decennium is echter 
de belangstelling voor verdere ontwikkeling van klassieke antibiotica sterk afgenomen 
(Projan and Shlaes, 2004). Hierdoor zijn er sinds de tachtiger jaren slechts enkele 
nieuwe antibiotica op de markt gebracht (Norrby et al., 2005). Het is duidelijk dat deze 
stagnatie tot grote gevaren voor de volksgezondheid kan leiden. Er is een dringende 
behoefte om de ontwikkeling van nieuwe antibiotica een nieuwe impuls te geven, in het 
bijzonder gericht tegen resistente bacteriën (Norrby et al., 2005). 
Het zou goed kunnen dat er zich onder de grote groep antimicrobiële peptiden 
(inmiddels zijn er meer dan 1000 beschreven) geschikte antibiotica kandidaten bevinden 
om resistente infecties te behandelen (Hancock, 1997; Zasloff, 2002). Om toekomstig 
onderzoek naar AMPs te bevorderen is het van vitaal belang om een betrouwbare 
screeningsmethode te ontwikkelen voor therapeutische doeleinden. Dit zou niet alleen 
de kans op het vinden van therapeutische AMPs tegen resistente bacteriën sterk 
vergroten, maar ook nog versnellen.
In onze studies hebben we aangetoond dat Dhvar-5 het aantal vitale bacteriën 
sterk kan verlagen in vivo. De data in ons model lieten echter duidelijk zien dat 
gentamicine superieur was in preventie van osteomyelitis. De hoge lokale afgifte vanuit 
het botcement maakt het onwaarschijnlijk dat Dhvar-5 effectiever zou zijn als het in 
een andere vorm zou worden toegediend (bijvoorbeeld systemisch). Daarnaast hebben 
wij aangetoond dat Dhvar-5 in relatief hoge concentratie hemolytisch werkt en toxisch 
is voor botcellen in vitro (Stallmann et al., 2005). Toekomstig onderzoek zou moeten 
worden gericht op het beter begrijpen van de farmacodynamische eigenschappen en 
het modiﬁ ceren van Dhvar-5 om de toxiciteit te verlagen.
Het antimicrobiele peptide hLF1-11 toonde daarentegen geen toxiciteit in vitro 
(Stallmann et al., 2005). Ook heeft dit peptide een uitstekende werking in vivo; er werd 
een zeer goede activiteit gevonden tegen multiresistente S. aureus en multiresistente A. 
baumanni in muizen (Dijkshoorn et al., 2004; Nibbering et al., 2001) en een zeer goede 
werking heeft in zowel preventie- als behandelmodellen van osteomyelitis in konijnen 
(Faber et al., 2005b; Stallmann et al., 2004). hLF1-11 heeft een groot potentieel als 
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een antibioticum zowel geïncorporeerd in botcement en als injectievloeistof. Om tot 
een klinische toepassing te komen moet toekomstig onderzoek gericht worden op het 
vinden van de meest geëigende toedieningsvorm en combinaties met conventionele 
antibiotica. Het is zeer aan te bevelen om na te gaan in hoeverre de verschillende 
AMPs synergistisch werken met de klassieke antibiotica, zoals bijvoorbeeld histatine-
5 met amphotericine B (van ’t Hof et al., 2000). Hierdoor kan de concentratie van 
beide antibiotica drastisch verlaagd worden, wat gunstig is voor het verminderen van de 
neveneffecten van antibiotica en voor het terugdringen van de resistentie. Eveneens zal 
er in de toekomst gezocht moeten worden naar goedkopere productiemethoden. Voor 
klinische toepassing zal ten slotte preklinisch onderzoek moeten plaats vinden.
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AMP  antimicrobial peptide
ANOVA  ANalysis Of VAriance between groups
ATCC   American Type Culture Collection
BCA  bicinchoninic acid
BHI   brain heart infusion
Ca-P  Calcium phosphate bone cement
cfu  colony forming unit
CNS  coagulase negative staphylococci
CZE  capillary zone electrophoresis
dH2O   demineralized water
Dhvar-5  synthetic histatin analogue
EDTA  Ethylene diamine tetra-acetic acid 
ESR   erythrocyte sedimentation rate
Fmoc   9-ﬂ uorenylmethoxycarbonyl
GRSA  gentamicin resistant Staphylococcus aureus
hLF1-11  human lactoferrin N-terminal amino acids 1-11
HPMC  Hydroxypropyl Methylcellulose 
IC50  Inhibitory Concentration 50%
ISO  International Organization for Standardization
KDL   department of experimental animal surgery
MIC  minimal inhibitory concentrations
min  minutes
MRSA   methicillin resistant Staphylococcus aureus
μ  micro
MPa megapascal
N number per group
NaCl Natrium Chloride
NZW New Zealand White
Ost-25 Osteopal® (commercial PMMA bone cement) with 25 mg Dhvar-5 / g cement 
powder
Ost-50 Osteopal® with 50 mg Dhvar-5 / g cement powder
Ost-100 Osteopal® with 100 mg Dhvar-5 / g cement powder
OstG Osteopal G® (commercial gentamicin containing PMMA bone cement)
OstG-25 Osteopal G® with 25 mg Dhvar-5 / g cement powder
OstG-50 Osteopal G® with 50 mg Dhvar-5 / g cement powder
PBS   phosphate buffered saline
PGFE  pulsed-ﬁ eld gel electrophoresis
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Abbreviations
PMMA   polymethyl methacrylate
psia  pounds per square inch, absolute
rBPI21  recombinant bactericidal/permeability-increasing protein
rpm  rotations per minute
sc  sub-cutaneous 
SD  standard deviation
SE  standard error
SEM  scanning electron microscopy
STEGA  Skeletal Tissue Engineering Group Amsterdam
SPSS  Statistical Package for Social Sciences
VRSA   vancomycin-resistant Staphylococcus aureus
WBC   white blood cell count
w/w%  weight/weight percentage
Ø  diameter



